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ABSTRACT 
Abstract 
The World Health Organisation estimates that 100 million people worldwide suffer 
from asthma. Chronic obstructive pulmonary disease (COPD) is the fourth leading 
cause of death worldwide. Pulmonary drug delivery is widely accepted as the first-
choice method for the treatment of respiratory diseases by glucocorticosteroids. 
Delivering these drugs to the lung by inhalation has many advantages in comparison 
to the same drug delivered orally. These include rapid onset of action, reduced dose 
and minimised side effects such as adrenal suppression, electrolyte imbalance, 
muscle weakness and growth retardation in children. Pulmonary drug delivery is also 
increasingly used for pain-controlling therapies and for administration of 
medications which are difficult to formulate orally such as proteins and peptides. 
The advantages of delivering drugs to the lung are undisputed, however, there are 
practical challenges still remaining to achieve repeatable and accurate dose delivery 
to the deep lung. An enabling technology for actuation-by-actuation, in-line 
measurement of pulmonary drug delivery is part of this greater challenge. The 
aerosol particles can penetrate into the deep lung only if their aerodynamic size is in 
the narrow range of O.5f.U1l to 5J.!m. The larger particles contribute to the 
oropharyngeal deposition diminishing the pulmonary-delivery advantages, and the 
smaller particles are exhaled. Particles of this size-range agglomerate easily through 
adhesion/cohesion interactions. Agglomerates have to disperse in the patient's 
inspiration fl ow. Therefore, the respirable dose and therapeutic efficacy depend on 
the drug formulation, the inhalation device, the ambient conditions and also heavily 
rely on the patient's inspiratory effort, which is highly variable. An ability to assess 
the efficacy of the pulmonary delivery in-line with a patient will ultimately improve 
the effectiveness and efficiency of medical therapy. 
This thesis presents a novel optical technology for non-invasive and in-line 
measurement of the respirable cloud during pulmonary drug delivery. The 
technology can be used as a stand-alone instrument, in conjunction with standard 
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laboratory analytic apparatus and ultimately in-line with a patient. It is shown how 
the technology concept is based on the Mie theory for light scattering by particles 
and on the Lambert-Beer law for light extinction by a turbid medium. A prototype 
device is developed to implement this concept and a series of experimental 
investigations are conducted to evaluate the feasibility of the approach. Comparisons 
between the novel in-line technology and conventional in vitro measurements using 
physical chemistry apparatus suggest that the approach can become a useful enabling 
technology in pulmonary drug delivery assessment. 
11 
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Chapter 1 
Introduction 
INTRODUCTION 
The recent proliferation in the use of pulmonary drug delivery has been fuelled by 
the success of biomedical research on inhaled systemic drugs and global concern 
over the sharp rise in respiratory conditions such as asthma and chronic obstructive 
pulmonary disease. The advantages of delivering drugs to the lung are well known, 
however, there are practical challenges still remaining to achieve repeatable and 
accurate dose delivery to the deep lung. An enabling technology for actuation-by-
actuation, in-line measurement of pulmonary drug delivery is part of this greater 
challenge. In this chapter we consider the complex nature of drug fonnulations for 
pulmonary delivery. The physiology of the human lung and standard methods for the 
efficacy evaluation are briefly introduced. The methods for particle characterisation 
have been researched to find a simple, in-line, non-invasive method for assessing an 
inhaler aerosol actuation. 
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1.1. Thesis overview 
Heightened interest in innovative pUlmonary drug delivery is fuelled by the 
emergence of inhaled systemic drugs and global concern over the sharp rise in 
respiratory conditions such as asthma and chronic obstructive pulmonary disease. 
The principal ,factor limiting the accuracy of the pulmonary delivered dose is an 
indirect assessment of the efficiency of the pulmonary delivery. The lack of an in-
line assessment means that an individual actuation cannot be measured and the 
patient inhalation effort is not taken into account. The aim of this thesis is to explore 
the possibility of an enabling technology for actuation-by-actuation, in-line 
measurement of a pulmonary delivery dose. 
This first chapter begins by introducing the complexity of pulmonary drug delivery, 
the standard assessment technologies and includes a discussion about methods for 
particle characterisation. The chapter concludes by stating the objectives and basic 
requirements for the possible in-line technology. 
In chapter 2 a model is developed that describes an aerosol cloud released by an 
inhaler and propagating through a cylindrical conduit for the purposes of measuring 
the optical density of the cloud. Numerical calculations using the Mie theory have 
examined the optical density 'signatures' for aerosol clouds of different particle 
distributions. The main principles for the technology are proposed in the chapter 
summary. The author has previously published some of these principles in the paper: 
Smith, P.R., Kusmartseva, O.E., Conway, J., Price, R., Morton, David A.V., 
Conway, P.P. and Summers, R., HE-Medic: Linking Informatics to a Dry Powder 
Inhalation System", Drug Delivery to the Lungs XIV, The Aerosol Society, DDL14, 
London, December 2003, pp. 4-7. 
Chapter 3 deals with practical issues of the proposed technology. At this early stage 
of the technology development, the major objective was to prove the concept rather 
than to optimise the measurement parameters. The chapter describes a prototype 
measurement device, data acquisition and analytical routine for the characterisation 
of the efficiency of the pulmonary delivery in-line with a user. For the first time a 
specific technical arrangement and analytical method have been developed and 
CHAPTER 1 
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tested. The methods described in this chapter are both previously published and filed 
at the U.K. Patent Office: 
O.E. Kusmartseva, AS. Kattige, R. Prise, P.R.Smith, "In-line assessment of 
pulmonary drug delivery using light obscuration", Biosensors and Bioelectronics 20 
(2004), pp. 468-474. 
A patent application for "Pulmonary Drug Delivery" was filed on 15th April 2003 
and is expected to be granted soon. 
Chapter 4 compiles the experimental results supporting the technology concept. For 
the first time it has been shown that the temporal profile of the light obscuration by 
an aerosol cloud provides an indicator for the amount of particles, which are 
regarded as fine particles for the pulmonary delivery and can reach the respiratory 
zone of the human lung. Strong correlation has been established between the novel 
and standard ways of assessing the pulmonary delivery efficiency through 
simultaneous measurements of the drug delivery. Some of these results have also 
been previously published: 
Kusmartseva, O.E., Smith, P.R. and Morton, D.A.V., "Comparing in-line optical and 
NGI measurements on a drug cloud", Drug Delivery to the Lungs XV, The Aerosol 
Society, DDLl5 , London, December 2004, pp. 183-186. 
Chapter 5 briefly reiterates the major achievements of the work and provides 
concluding remarks. Recommendations are also made for further studies in this area. 
The references are collected in a single section following the main body of the 
report. 
CHAPTER 1 
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1.2. Pulmonary drug delivery 
The potential advantages of delivering a drug to the lung by inhalation have been 
well known to scientists, physicians and also to drug abusers for many years. For 
drugs that exert their biological effect in the lung, these advantages include rapid 
onset of action, reduced dose and minimised side effects in comparison to the same 
drug delivered orally. Pulmonary drug delivery is widely accepted as the first-choice 
method for the treatment of obstructive airway diseases such as asthma or chronic 
obstructive pulmonary disease (COPD) (British Thoracic Society, 2003), because it 
minimises the problems associated with oral corticosteroids such as adrenal 
suppression, electrolyte imbalance, muscle weakness and growth retardation in 
children (Bames et al., 1993; Geddes, 1992; Lipworth, 1992;). Future applications 
for pulmonary drug delivery can be in areas of therapeutic peptide/protein drugs 
(Adji et al., 1997). These drugs are difficult to formulate orally due to either 
enzymatic instability or non-permeability through the gastrointestinal membrane, 
and therefore must be i~ected into the blood stream. The lung's large absorptive 
area, thin alveoral epithelia and extensive vasculature make it an attractive, non-
invasive route for the administration of these systemic drugs. 
There are three major patient groups which will benefit from effective pulmonary 
drug delivery. Namely: 1) asthma patients for symptom-managing therapies; 2) 
diabetics for a non-invasive insulin treatment and 3) cancer patients and pain-
sufferers for pain-controlling therapies. 
The therapeutic efficacy of the pulmonary drug delivery is a very complex issue and 
strongly depends on four major components: I) the drug itself as an active 
pharmaceutical ingredient; 2) the drug formulation, which facilitates the drug 
reaching the targeted part of the respiratory system; 3) the delivery device, which 
produces an aerosol cloud of the drug formulation and 4) the patient, who is able to 
use the delivery device correctly. Since pulmonary drug administration is directly 
related to the human respiratory structure and function and to the approaches of drug 
formulation being introduced into the lung, any discussion requires a thorough 
understanding of these fundamentals. 
CHAPTER 1 
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1.2.1. Physiology of the lung 
1.2.1.a. Lung structure 
The human respiratory system is a complicated organ system of close structure-
function relationships. To fully understand the impact of respiratory structure and 
function on drug delivery, some aspects of the anatomical structure and functional 
physiology of the respiratory system are set out below. 
'\ 
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Figure 1.1. Graphical illustration of the human respiratory tract. 
The respiratory system (Figure l.l) is functionally composed of two major regions: 
the conducting airway and the respiratory region. The conducting airway is 
composed of the nasal cavity and associated sinuses, mouth, oropharynx, larynx, 
trachea, bronchi, and bronchioles, including the first 16 generations of airways of 
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WeibeI's tracheobronchial tree (Weibel, 1963). These structures are incapable of 
performing gas exchange with the venous blood, but are lined with a viscoelastic, 
gel-like mucus layer (Sanderson, et al., 1981). This protective mucus blanket entraps 
and removes the inhaled particles from the airway. Before reaching the respiratory 
region, the true area of gas-exchange, the inspired air is filtered, heated to body 
temperature and humidified as it passes through the conducting airway. The 
respiratory region is composed of respiratory bronchioles, alveolar ducts, and 
alveolar sacs, including generations 17 to 23 of Weibel's tracheobronchial tree. The 
main function of the respiratory region is to facilitate the rapid gas exchange 
between the inhaled air and the blood stream. 
Table 1.1. Structural characteristics of the human respiratory system. 
N" nb DC, [mm] 
Trachea 0 1 18 
Main bronchi 1 2 13 
Lobar bronchi 2-3 4-8 7-5 
Conducting Segmental 4 16 4 
zone bronchi 
Small bronchi 5 - 11 32 - 2,000 3 - 1 
Bronchioles 12 - 16 4,000- 1-0.5 65,000 
Respiratory 17 - 19 130,000- 0.5 
Respiratory 
bronchioles 500,000 
1,000,000-
zone Alveolar ducts 20 - 22 0.3 4,000,000 
Alveolar sacs 23 8,000,000 0.3 
a) N is the ~eneration of Weibel's tracheobronchial tree; b) n is the number of 
structures; C D is the diameter of the structures (Weibel, 1963). 
The mean diameter of the adult human trachea is about 1.8 cm (Table 1.1). As it 
branches progressively, its diameter decreases to 1 mm at the 11 th generation, 
corresponding to a dramatic increase in total cross-sectional area (Weibel, 1963). 
The calibre of following generations of airways is a function of the lung volume, 
since the forces holding their lumina open are stronger at higher lung volumes. After 
CHAPTER 1 
6 
INTRODUCTION 
the 11 th generation, the number of bronchioles increases far more rapidly than the 
calibre diminishes (Table 1.1). Branching into the respiratory region, airway 
diameter does not change significantly, however, the enormous increase in the 
number of alveolar ducts results in an exponential increase in total cross-sectional 
area and, therefore, a significant decrease in the velocity of airflow. The total surface 
area of the lung is about 80 square meters, equivalent to the size of a tennis court. 
Only about 10% of the lung is occupied by solid tissue, whereas the remainder is 
filled with air and blood. Two circulation processes occur in the lung: the air 
circulation or ventilation and the blood circulation for perfusion. Pulmonary 
circulation carries almost the same blood flow, approximately 5 litres per minute, as 
the whole systemic circulation. 
The lung structure makes it a very effective organ for administrating a substance into 
the blood stream since, as soon as this substance can be delivered to the respiratory 
zone of the lung, it is able to penetrate the air-blood dividing membrane. 
1.2.J.b. Lung ventilation 
The air circulation is accomplished by a well-coordinated interaction of the lung 
with the central nervous system, the diaphragm and chest wall musculature. The 
respiratory cycle consist of an inspiration followed by expiration. It can be presented 
as a breathing profile describing the flow rate entering the oropharynx as a function 
of time. The airflow interacts with particles suspended in it, therefore the flow rate 
defines the speed of the particles in the contacting zone of the lung and hence the 
entraimnent process of the drug formulation. As the air enters into the branching 
structure of the lung, the flow rate decreases due to the progressive increase of the 
total cross-section of the airways. The viscosity forces of the particle-air interaction 
slow particles down, while the particle inertia causes particle impaction on the 
airway walls. There is a fine balance between the particle size and the flow rate that 
allows the particle to follow the air stream into the deep lung. 
In principle, by controlling the efforts applied to the musculature, humans can 
produce a variety of inspiratory flows, although the variety is rather limited due to 
the human physiology. Eventually everyone can be trained to be able to produce a 
reasonably chosen breathing profile. For example, in leaflets of so-called pressurised 
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metered dose inhalers (p-MDIs), commonly used in the asthma managing therapies, 
patients are required to produce a slow long inhalati on fo llowed by holding the 
breath for several seconds before breathing out slowly. Such breathing enhances the 
penetration of the drug into the deep lung and, therefore, facilitates the effective 
relief of the acute asthma symptoms. Unfortunately, under asthma attacks patients 
may lose some muscle contro l, and as a result of thi s they fa il to produce the 
required breathing effort and thus fai l to receive the requ ired dose of drug, when 
they most need it. The breathing profi le influences the efficacy of the pulmonary 
drug delivery and is one of the major parameters fo r engineering purposes of 
designi ng a successful pulmonary drug therapy. Figure 1.2 presents a few typical 
inhalation profiles produced by humans in comparison to the vacuum mode of the 
breathing machine. 
150 
- human 1 
~ 120 - human 2 c 
E - human 3 
--l 90 - vacuum pump ~
Q) 
-re 0::: 60 
~ 
0 
u.. 30 
0 
0 1 2 3 
Time , [sec] 
Figure 1.2. Variety of inspiratory profiles. 
Alternatively, physicians discuss an airflow in and out of the lungs as a function of 
the pressure gradient between the alveoli and the atmosphere, with the pressure 
gradient changing through alterations in the dimensions of the thoracic cavity and 
subsequently of the lungs (Sherwood L., 200 1). The flow rate F through airways 
depends not only on the pressure gradient M but also on the airway resistance to 
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the flow R with F = t:,p . The primary determinant of resistance to airflow is the 
R 
radius of the conducting airways. In a healthy respiratory system, the radius of the 
conducting system is sufficiently large that resistance remains extremely low. It 
needs only very small pressure gradients of I to 2 mm Hg to achieve adequate rates 
of airflow in and out of the lungs. Resistance becomes an extremely important 
impediment to airflow when airway lumens become abnormally narrowed as a result 
of disease. When airway resistance increases, a larger pressure gradient must be 
established to maintain even a normal airflow rate through increased respiratory 
muscle exertion. Accordingly, patients with COPD and asthma have to work harder 
to breathe. Due to the specifics of the lung physiology, the airway resistance during 
an inspiration is lower than during the expiration. In a nomlal individual, the airway 
resistance is always so low that the slight variation occurring between inspiration 
and expiration is not noticeable, but with an increase of the airway resistance the 
difference between inspiration and expiration becomes quite noticeable. 
- - - - - - - - - - 6D 
Maximal Inspiratory 
le",,1 
-------Maximal e"l'iratory 
le",,1 
~ 
co 
~ 
~ 
Cl> 2.7 E 
::> 
2.20 
'" 
~~~~L-~ __________________________ ~D 
IRV = Inspirarory Reserve Volum e 
ERV = Expiratory Reserve Volume 
TLC = Total Lung Capacity 
FRC = Functional Residual Capacity 
TV =Tidal Volume 
RV = Residual Volume 
VC = Vital Capacity 
Figure 1.3. Standard (static) lung volumes as measured with a spirometer. 
The changes in lung volume that occur with different respiratory efforts can be 
measured using a spirometer device. Figure 1.3 shows a hypothetical example of a 
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spirogram in a healthy young adult male. A number of different lung volumes and 
lung capacities (a lung capacity is the sum of two or more lung volumes) can be 
determined from the spirogram and are presented in Table 1.2. Measurement of the 
lungs' various volumes and capacities is of more than academic interest, because 
such detenninations provide a useful tool to the diagnostician in various respiratory 
disease states. This method is also adopted by physicians and allows an in-vivo 
evaluation of the effectiveness of the pulmonary drug delivery in asthmatic patients. 
For example, measuring FEV 1 before and after the drug intake gives an indication of 
the change of the maximal airflow rate that is possible from the lungs. Thus, the 
effect of the drug onset on the airway resistance can be measured, and therefore, the 
efficacy of pulmonary delivery can be established. 
Table 1.2. Lung Volume Definitions. 
Lung Volumes Definition 
Tidal volume (TV) The vo lume of air entering or leaving the lung 
at each breath 
Inspiratory reserve volume (IRV) The volume of air maximally inspired after a 
normal tidal inspiration 
Expiratory reserve volume (ERV) The volume of air maximally expired after a 
normal tidal expiration 
Residual volume (RV) The volume of air left 1I1 the lung after 
maximal forced expiration 
The volume of air remaining in the lung at the 
Functional residual capacity (FRC) end of normal tidal expiration 
(FRC=ERV+RV) 
Inspiratory capacity (IC) The volume of air maximally inspired after a 
normal tidal expiration (lC=IRV+TV) 
The volume of air maximally expired after a 
Vital capacity (VC) maximal forced inspiration 
(VC=IRV+TV+ERV) 
Total lung capacity (TLC) The volume of air in the lung after a maximal inspiratory effort (TLC=VC+RV) 
Forced expiratory volume in one The volume of air that can be expired during 
the first second of expiration after a maximal 
second (FEV I) forced inspiration. 
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1.2.2. Pulmonary drug formulations 
Pulmonary drug formulations are intended for lung deposition and are usually 
prepared in the form of a powder or a liquid solution. With the help of a delivery 
device the formulation is dispersed as an aerosol that propagates through the 
respiratory system aiming to deposit the majority of the drug into the respiratory 
zone of the lungs. The principal mechanisms contributing to lung deposition are 
inertial impaction, sedimentation and diffusion (Heyder et al., 1986). The 
aerodynamic dian1eter (d,,) of an aerosol particle defines the inertial impaction and 
sedimentation, while the geometric diameter (d g) controls diffusion. Most authors 
agree that only particles in the aerodynamic range of 0.5 ~lm to 5 ).Im contribute to 
the deep lung deposition (e.g. Vidgren, 1994). The larger particles are absorbed in 
the upper parts of the respiratory system mostly due to the inertial impaction on 
walls. The smaller particles are usually exhaled. The other specific parameter of the 
pulmonary formulation is the particle flowability. Particles of geometric diameters in 
the range of 0.5 ).Im to 5 ).Im are very cohesive and usually aggregate in clusters. 
These clusters have reasonable flowability, but if they have failed to de-agglomerate 
in the airflow they will impact onto the oropharynx and do not contribute to the lung 
deposition. The liquid fom1Ulations must be sprayed . Droplet sizes are defined not 
only by the spraying mechanism, but also by the ambient conditions such as air 
temperature, humidity and flow rate, whjch control the evaporation process during 
the aerosol propagation and thus the final sizes of the droplets. 
The pharmaceutical industry makes enormous efforts to develop drug formulations , 
which have to provide a good lung deposition of the medication. Here are a few 
major types of existing pulmonary formulations: 1) drug solutions or drug 
suspensions, dispersed by a suitable jet-device into a cloud of fine droplets; 2) dry 
powders of micro-fine drug particles, so-called drug-only formulations; 3) dry-
powder mixtures of carrier particles (larger particles with a good flowabi li ty) and 
micro-fine drug particles, which make adhes ive bonds with the carrier particles and 
easily separate from them in the airflow; 4) porous particles with relatively large 
geometric diameters (>5).1m) and low mass densities, yielding the aerodynamic 
diameters that are optimal for the lung deposition. 
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1.2.3. Delivery devices 
Delivery devices are developed to di sperse drug fo rmulations in the form of an 
aerosol. Deli very devices must fulfil numerous requirements concerning operation 
principles and patients' preferences. The most popular and mainly prescribed by 
doctors are hand-held devices: either pressurised metered dose inhalers (p-MDls) or 
dry powder inhalers (DPls). Although both types of inhalers have been extensive ly 
investigated (the most resent publications: Meak in et al. , 1995 ; Hindle et al ., 1995; 
Kamin et al., 2002) and many efforts have been made to improve their performance, 
some problems are still associated with the ir use (Bisgaard et aI., 1998; Feddah et 
al., 2000). 
1.2.3.a. Pressurised metered dose inhalers 
In the traditional p-MDI (Figure 1.4). fine powder partic les a re di spersed in 
hydrofluo roa lkane (HFA) prope llants, or the drug is di ssolved with the aid of a co-
so lvent, and then sealed under high pressure in an aluminium callister. Surfactants 
may be added to prevent agglomeration of the particles. Press ing the canister down 
into the actuation seating allows the va lve to release a metered volume of the 
contents from the metering chamber; the droplets emerge into the air at high speed 
and , until the propellants have evaporated, are generall y quite large (40 ~m) 
(Pedersen, 1995). 
Figure 1.4. A typical pressuri sed metered dose inhaler (MOL). 
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When using MDIs, a correct inhalation technique is necessary. The optimal lung 
deposition is enhanced by a slow deep inhalation followed by holding the breath for 
several seconds before breathing out slowly (Pauwels et a/. , 1997). In addition, the 
MD! inhalation routine requires shaking the device to ensure even distribution of the 
drug, breathing out before placing the lips around the mouthpiece, and coordinating 
the device-actuation with the stalt of the slow inhalation. Studies have shown an 
alarming degree of incorrect usage, with a typical fai lure rate of around 60% for 
slow inhalation and well-timed actuation (Ganderton et aI. , 1997). Many patients 
also have difficulty in continuing the inhalation fo llowing actuation due to the shock 
effect of fast-moving ' cold freon' , when the propellant spray hits the back of the 
throat (Crompton, 1982; Ganderton er al. , 1997; Hilton, 1990). Poor synchronisation 
decreases the lung deposition and increases the oropharyngeal deposition, which 
induces local and systemic side effects. 
1.2.3.b. Dry powder inhalers 
Dry powder inhalers (DPIs) are used for di spersion of the powder drug fo rmulations. 
They are inherently breath activated, releasing drug when the patient inhales. The 
inspiratory airflow of a patient provides the sole energy source to disperse the drug 
particles and to move the aerosol ised particles from the body of the inhaler to the 
lungs (Prime et al., 1997). In practice, the patient' s inspiratory effort wi ll determine 
the entrainment and dispersion performance and hence the dose delivered by DPIs to 
the lungs. Individual users may not always actuate the dose consistently and some 
users may be unable to impart sufficient force to generate an effective dose (Hickey 
et al. , 1994; Newman et af., 1988). The patient inconsistency causes a huge variation 
in the dose delivered by DPIs, although the formulation and the device also play 
important parts in achieving accurate, deep-lung deposition. 
1.2.3.c. Nebulisers 
In intensive care units and in the more serious cases, when the hand-held devices 
have fai led to control disease symptoms, another type of delivery device is used, 
namely the nebuli ser. Nebulisers are pulmonary delivery devices, which produce 
droplets constantly from a dilute aqueous drug solution. The internal geometry of 
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conventional nebuli sers and their operation are highly variable (Dalby et al. , 2003; 
Niven, 1996). A schematic diagram of an air-jet nebuliser is shown on Figure 1.5. In 
these systems, pressurised gas is forced through a narrow nozzle, which generates a 
region of low pressure at the orifice. TIlls negative pressure is used to augment 
capi llarity and draw the drug solution from the bulk into the fast moving air-stream. 
The bulk drug solution is sheared first into a thin sheet of expanding liquid and 
ultimately into a range of fast moving droplets with a range of particle sizes. The 
droplet stream is directed into a so lid surface or baffle. Baffles serve to capture 
larger droplets by inertial impaction allowing only smaller ones, suitable for lung 
delivery, to be entrained in the air-stream leaving the cup of the nebuliser. The 
trapped droplets return to the bulk solution. The re-circulation of the drug solution 
results in the temperature fa ll of the bulk liquid and droplets due to evaporative 
cooling. The drug solution concentrates due to the loss of water vapour. A nebuliser 
typically takes 10-1 5 minutes to administer a single dose, because most of the bulk 
drug solution is not converted to an inhalable aerosol in a single pass tJrrough the 
nozzle. 
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Figure 1.5. Schematic diagranl of an air-jet nebuliser: compressed air enters 
through a narrow tube (A), causing a pressure drop near the venturi (B); the liquid 
drug formulation is rising from the reservoir (R) and the jet air stream breaks it up 
into droplets of various sizes; larger drop lets fall back into the reservoir deflected 
by the baffle (C); small droplets leave the nebuliser with the jet stream as a fine 
mist that is inhaled by the patient (P). 
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Nebulisers retain two important advantages over other aerosol delivery systems. 
First, nebulisers require no complex breathing manoeuvres and therefore no training. 
They deliver aerosols over multiple breaths and tidally breathing patients, breathing 
spontaneously, or on a ventilator, can be dosed so long as the outlet of the nebuliser 
remains connected to their inhaled air-stream. Second, because the volume of 
solution is large and inhaled over multiple breaths, larger doses of drug can be 
administered compared to the hand-held inhalers. The ability of patients to use 
nebulisers intuitively, without training, and their ability to deliver some of the drug 
(if not the optimum amount) continues to preserve their use for ambulatory and 
intensive care (British Thoracic Society, 2003). 
1.3_ Efficacy evaluation 
1.3.1. Introduction 
The ultimate goal of eval uating the efficacy of pulmonary drug delivery is the ability 
to measure the amount of the drug, which actually reached the targeted part of 
respiratory system of an individual patient. For asthma-controlling therapies the 
targeted part of respiratory system is the deep lung. It is not enough to evaluate a 
drug formulation in respect to particle properties such as particle shape, particle size 
distribution and homogeneity of the drug distribution over the formulation, which 
can be measured by common methods of size analysis (Fayed et al., 1984). The 
evaluation task is more related to the characterisation of the particle size distribution 
in an aerosol released by a delivery device and entering the patient's respiratory 
system. Engineers designing a pulmonary delivery device have to evaluate the dose 
released by the device, the amount of respirable fine particles in the released dose 
and the variability of these parameters over multiple device actuations. Physicians 
have to evaluate if an individual patient is getting a prescribed dose of the drug by 
using a particular inhaler-device with a particular drug fommlation. 
The success of pulmonary delivery is the culmination of a series of events: a drug is 
blended into a formulation, this formulation is released by a delivery device in the 
form of an aerosol with a high proportion of the fine particles, and a patient 
effectively inhales this aerosol into the deep lung. To evaluate this complex process 
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there currently exists a number of ri gorous testing steps, which can be divided into 
two major groups: in vivo and in vitro characterisations, although neither of them 
resolves the ultimate task. 
1.3.2. In vivo assessments 
In-vivo investigations of pulmonary drug efficacy are normally performed on a 
group of patients or vo lunteers to establi sh a variation caused by the patient and a 
distribution of drug between the oropharynx and the respiratory zone. The results 
determine the pulmonary avai lability of the drug and its variation for users . The 
main methods for in vivo measurement of the pulmonary availability of inhaled 
material are: Gamma Scintigraphic lmaging, the Pharmokinetic method and Lung 
Function Tests (Sherwood L., 200 I). 
1.3.2.a. Gamma (rJ - Scintigraphy 
For y-scintigraphy the drug formu lation is labelled with a radioacti ve iso tope, 99mTc 
(Fleming et al. , 2000; Fleming et al. , 2001 ; Warren el al., 2002). Upon the drug 
administration a gamma camera takes images of the upper half of the human body. 
The dose distribution over the respiratory system is analysed by the contrast in the 
image related to y-counts. This method measures only the relati ve amount of the 
drug in the different parts of the respiratory system. 
Gamma-Scintigraphy of lung deposition provides valuable data on the site-specific 
drug deposition in the patient's lung. The drawbacks of this technology relate to the 
radiolabelling of the drug. This means that the drug fo rmulation has been modified 
by the radio labelling and may have quite different aerodynamic properties, which in 
turn will affect the lung deposition. The implementation of Gamma-Scintigraphy 
a lso involves complex and sophisticated protocols, including ethical approvals, 
without mentioning the risk of subjecting individuals to y radiation. 
J.3.2.h. Physiological characterisation 
Physiological characterisation evaluates the clinical efficacy of drug administration 
by measuring specific functions of the human body. In pharmokinetic tests, the 
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amount of drug can be directly measured in blood and urine samples. Blood and/or 
urine samples are co llected at the pre-set time intervals after the drug administration. 
A plot of the drug concentration in plasma/urine, presented as a function of time, 
allows measurements of the maximum drug concentration, the terminal half-life and 
the area under curve (AUC). To deduce the absolute amount of drug taken by the 
lungs requires specific physiological methods, including the gastro-intestinal 
absorption and the liver metabolism. 
In lung function tests, the so-called forced expiratory volume in 1 second (FEY 1) is 
measured before and after the drug administration (Hughes, 1999). [n asthma 
management this method allows the direct measurement of the physiological effect 
of the drug on the respiratory function of the patient (e.g. Serra-Batlles et al. , 2002). 
Physiological tests have a very important role in the patient-centred assessment of 
medications, although such tests clearly always require ethical approval and hence 
must have a predicted health benefit. Usuall y, these tests are unable to answer the 
questions about which particular part of the delivery device or drug form ulation is 
responsible for any changes in the medical outcome. 
1.3.3. In vitro assessments 
In vitro methodologies have evolved to assess " like in vivo" behaviour of the 
pulmonary delivery system. They remove the unpredictable features of the patient 
variability and provide the preliminary data on deposition patterns. In vitro 
measurements can eva.1uate a prototype or a novel delivery system; the development 
changes of formulations and provide vital information on the combined performance 
of the device and the formulation prior to volunteer trials. They estimate also batch-
to-batch variations and give a good indication on how a system wi ll perform in 
clinical studies. 
1.3.3.0. Aerodynamic size distribution 
For pulmonary delivery, the key parameter is the particle aerodynamic diameter. 
Consider the pulmonary dose as a single aeroso l cloud released by a delivery device. 
In this cloud there are populations of particles of different aerodynamic diameters. 
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The fo llowing values are the mam parameters, which are normally used to 
characterise the pulmonary dose delivery. The Mass Median Aerodynamic Diameter 
(MMAD) and Geometric Standard Deviation (GSD) characterise the cloud as a 
whole, giving the aerodynamic diameter and its deviation for the particles, which are 
responsible for 50% of the cloud mass. The amount of drug available for the deep 
lung deposition is the Fine Particle Dose (FPD) and is measured as the mass of the 
particles with aerodynamic diameters in the range between approximately 0.5 Jlm 
and 5 Jlm depending on the measurement apparatus . The Metered "Labelled" Dose 
(MD) is the drug mass in a single dose labelled by the producer: for a pMDI it is the 
dose measured by the metering valve; for a DPI reservoir device it is the dose 
measured by a dosing chamber and for a single dose blister it is the drug mass inside 
the blister. The Emitted Dose (ED) is a drug mass, which has been released from the 
delivery device dw·ing a single actuation. The Fine Particle Fraction (FPF) is defined 
as the percentage of the delivered dose that can penetrate into the deep lungs: 
FP F = FP D * 100%. During in vitro studies these parameters are measured and 
ED 
statistically evaluated for different batches of the same drug formulation, for 
multiple actuations from the single inhaler device and for performance across 
multiple devices. If these statistical variations are within the regulatory requirements, 
the given combination of the drug form ulation and the delivery device is allowed for 
further in vivo testing with volunteers and patients. 
I.3.3.b. Inertial impaction method 
British, European and US Pharmacopoeias (Bri tish Pharmacopoeia, 1993; United 
States Pharmacopeia, 2000) require that the in vitro tests have to be performed by 
means of an inertial inlpaction device (Olsson et al. , 1996). The recommended 
inertial impaction systems are: the Andersen Cascade Impactor, the Marple Miller 
Cascade Impactor and the Multi-stage Liquid Impinger. The Next Generation 
Pharmaceutical Impactor (NGI) has now been rigorously tested (Asking et al., 2003) 
and may soon be reconunended by the Pharmacopoeia. 
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A cascade impactor can have 3 or up to 12 stages mimicking the various parts of the 
human respiratory system. The impactor is designed such that, as the aerosol stream 
passes through each stage, particles having a large enough inertia will impact upon 
that particular stage plate whilst smaller particles wi ll pass to the next impaction 
stage. Figure 1.6 shows a simple model of the impaction process. As the direction of 
flow changes, aerosol particles continue to move in the original direction wltil the 
viscosity friction slows them down. Then they " relax" into the new flow direction 
(Relaxation Time). Placing a collection surface normally to the original fl ow causes 
the particles, which have insufficient relaxation time to impact. Small particles relax 
more quickly, thus do not impact. By controlling the number of j ets, their diameters 
(W) and the impaction stage separation (S) the effective cut-off aerodynamic 
diameter can be controlled at various flow rates (Rader et aI., 1985). For a cascade 
impactor operating at a given flow rate, each stage directl y relates to a cut off 
aerodynamic diameter. Chemical analysis of each impactor stage all ows the mass 
versus size interpretation of the aerosol contents. And therefore it is poss ible to 
calculate all parameters that we have defined for in vitro characterisation. 
w 
Figure 1.6. Schematic presentation of the inertial impaction process: small 
particles follow the streamline (solid lines); the trajectory of a large particle 
(dashed line) intersects the impaction plate; S is the nozzle-to-plate di stance 
and W is the nozzle diameter. 
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J.3.3.c. Limitations of cascade impactors 
Impactor measurements are influenced by many factors such as the precision of the 
mechanical manufacturing of the impactor's components, tbe stability of the flow 
rate (Rader et al., 1985), ballistic bOlmce and re-entrainment ofpartic!es from stages 
(Hickey, 1990) and the accuracy of an operator. But major concerns are related to 
the principal drawbacks: I) the relation between stages and particle sizes is only 
valid for a given, constant flow rate of the air and therefore the patient respiratory 
effort cannot be taken into account; 2) due to the sensitivity limits of the chemical 
analysis, the results are an average over multiple doses; 3) the measurements are 
extremely time and labour consuming and 4) an automation of the measurement 
process is not available and has proved difficult to develop. 
Despite the efforts of manufacturers to develop a labour saving impactor, the most 
robust and modern designs involve at least 25 minutes to collect samples from the 
stages and prepare for the next test. The analysis of the samples takes even more 
time. Attempts to develop automation for measurements of a cascade impactor 
appear to be very costly and ineffective. The next generation pharmaceutical 
impactor (NGI) was designed with the intention that the automation routine wi ll be 
easier to develop and app ly. 
The more stages that are present in the impactor, the more the particle size classes in 
the particle distribution that can be measured. Since the an10unt of drug delivered in 
each dose is relatively small, there is a limit to the number of stages that can be used 
for a single actuation analysis. It is therefore usual for results from cascade 
impactors with four or more stages to be based upon the average values over a 
number of actuations (often 5). This results in the in vitro data normally 
overestimating the performance of the pulmonary therapy in comparison to the in 
vivo investigation, where dose evaluations are normally based on a single actuation. 
l.3.3.d. Link to humans 
Recently, attempts have been made to address the issue of the human respiratory 
airflow in the inertial impaction investigations (Burnell et aI. , 1998; Chavan et al., 
2000; Chavan et al., 2002). An individual patient can create rather an individual 
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cloud of drug formulation due to hi s/her particular inhalation flow profile, and 
therefore he/she will get an individual dose of the drug. A novel method has been 
developed to assess the 'like in-vivo performance' ofDPIs using the Electronic Lung 
Device (Bumell et al. , 1998). The computer-controlled breathing simulator creates 
des ignated inhalation airflow, which disperses the drug dose from DPI into the 
holding chamber. Then, another vacuum pump draws the drug cloud from the 
holding chamber through a cascade impactor at the fixed flow rate to determine 
particle sizes. In this way the dose dispersion process is entirely separated from the 
particle sizing process, therefore an individual patient may be assessed. However, 
this method still requires labour-consuming measurements of the cascade impactor 
and the holding chamber may influence the particle distribution. 
Richard Dalby's team from the Uni versi ty of Maryland proposed a control system 
and valves capable of ramping up to the predetermined peak of an airflow through a 
DPI in conjunction with the in vitro testing apparatus MSLl (Chavan et al. , 2000; 
Chavan et aI. , 2002). These modifications allow the study of the effects of the 
different parts of the flow-rate profile on the deposition pattern during in vitro tests, 
for example, the effect of the rising edge of the profi le and how quickly the flow rate 
reaches the maximum. 
1.3.4. Needs for a fast, non-invasive, patient-related assessment 
Developing novel therapies for pulmonary drug delivery, a match between a 
formulation and a device, should be based on data. The data should be co llected on 
both the drug and device before the match is made. Regulatory tests (in vitro and in 
vivo) are not the best tools for device/formulation development or screening (Dalby 
et al. , 2003). In vitro measurements are precise and sensitive, but completely 
irrelevant to the patient vari ability and are extremely time and labour consuming. In 
vivo studies are accurate in determining the drug deposition into the respiratory 
system, but are completely inapplicable to the early stages of developing either 
delivery systems or drug formulations. Therefore, there is a need for a different 
method of aerosol characterisation. Emerging teclmologies are looking for a quick 
(not necessarily metrological) testing procedure that can help to narrow down 
options rapidly. 
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A treatment of a patient by a pulmonary therapy strongly depends on the ability of 
the given patient to use successfully a given inhaler. Currently, patients are only 
advised to ensure a particular inspiration flow during the drug intake, without any 
means to evaluate the actual aerosol released by the inhaler at this particular 
actuation. For some patients the asthma controlling therapy is not working, and 
doctors are faced with the dilenillla of whether to increase the drug dose or to switch 
to a different inhaler. Eventually, by mUltiple try-and-see cycles, the right inhaler 
and the right dose are found. It is undoubtedly beneficial for patients if the 
pulmonary drug delivery can be evaluated routinely, in real time, actuation-by-
actuation. Obviously, the existing in vivo methods are unsuitable for this task. 
Patients and developers of the pulmonary delivery systems would all benefit from a 
robust technology that is able to characterise the amolUlt of fine particles in the 
released drug cloud through in situ measurements. Such technology can also help to 
constantly monitor the patient's performance with respect to therapy compliance and 
device suitability. The following is a list of desirable features for emerging 
technologies: 
• It is fast in comparison with usual cascade impactors. Then, the method can 
shorten the time taken searching for promising ilillovations. 
• The fine particle dose (FPD) and fine particle fraction (FPF) of the released 
dose are the most desirable values rather than a precise particle size 
distribution. 
• The desired object for the characterisation is the real aerosol cloud actuated 
by a realistic airflow. Therefore, the metllOd is in situ and in-line with a 
patient. 
• The measurement affects neither the aerosol nor the airflow. Thus the method 
is non-invasive. 
Section 1.4 discuses the possible method for an in-line, non-intrusive 
characterisation of the pulmonary drug delivery. 
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1.4. Methods for particle characterisation 
1.4.1. Overview 
Dispersion processes and the shape of particles makes particle size analysis a more 
complex matter then it first appears. The first issue is that particles are three-
dimensional objects and generally speaking have to be described with three or more 
numbers. Secondly, there are a huge number of different particles in the sample to be 
analysed. For example, a typ ical single dose of Pulmicort® Turbohaler® contains 
200llg of budesonide . Then, if all released particles are respirable spheres of Illm 
diameter, the total number of particles in the dose cloud wi ll be 250 millions (the 
budesonide density is 1.54 g/cm\ Moreover, different methods measure a different 
aspect of the particle size. While imaging techno logies such as optical or electron 
microscopy are looking at some two-dimensional projection and a sieving method 
characterises the minimal sizes of particles, laser diffraction can give particle 
vo lumes. For management purposes, to be able to compare different doses on the 
basis of their mean particle size and particle size distribution, it is convenient to be 
ab le to describe a three-dimensional object by one unique number. This requires an 
examination of the Equi valent Sphere Theory. 
1.4.1.a. Equivalent sphere theory 
Only spheres are exactly described by one parameter, their diameters. There are a 
number of properties of an arbitrary-shaped particle that can be described by one 
number. For example, the weight is a single w1ique number as is the vo lume and 
surface area. So if we have a technique that measures the weight of the particle, we 
can then convert this weight into the weight of a sphere and calculate one unique 
number for the diameter ( 2 . r) of the sphere of the same weight as the arbitrary-
shaped particle: 
. h 4 3 
welg t = '3 'TC • r . P , where p is the density. Now, by measuring 
some property of our particle and assuming that this refers to a sphere, we can derive 
one unique number (the diameter of this sphere) to describe our particle. This 
ensures that each three-dimensional particle is described by one lli1ique number 
which, although less accurate, is more convenient for management purposes. Table 
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1.3 shows typical methods of expreSSIng size measured by several different 
techniques . 
Table 1.3. Definitions of equivalent sphere diameter. 
Volume diameter The diameter of the sphere having the same 
volume as the particle 
The diameter of the sphere having the same 
Projected surface diameter projected area as the particle profile In the 
position of rest 
Surface diameter The diameter of the sphere having the same 
surface area as the particl e 
Stokes ' diameter The diameter of the sphere having the same 
terminal velocity as the particle 
Particle sieve diameter The width of the mInim um square aperture 
though which the pm1icle wi ll pass 
Specific surface diameter The diameter of the sphere having the same ratio 
of external surface area to volume as the particle 
1.4.J.b. Common methods oJsize analysis 
Many technologies have been developed using different physical principles for 
measuring particle size. Table 1.4 shows some of the size analysis methods that are 
commonly used in practice. The techniques range from the mechanical Size 
separation (sieving) to the size evaluation based on particles' interaction with 
radiation. Some methods measure sizes of individual particles and can hardly be 
applied for in-line or in situ measurements . The others use additional forces like 
gravitational and centrifugal forces or require particles to enter the measurement area 
one-by-one; therefore they also cannot be applied for in-line applications. The last 
column in Table 1.4 shows that only a few techniques can be used for in-line 
measurements: these are optical and ultrasonic methods. 
For meaningful size analysis, each particle should be individually dispersed and be 
stable with regards to coagulation. Because the way in which the dispersion is 
carried out can drastically affect the size measurement, a general rule is to measure 
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particles by a method that is closely related to its end-use properties and in the 
medium in which it is used. For the reason that ultrasound methods normally require 
a liquid sample, they have significant disadvantages in comparison with the optical 
methods for the purpose of characterising pulmonary drug delivery. Taking into 
account that optical methods are quick, non-invasive and ab le to operate on dry 
samples (aerosols), optical principles appear to be the most promising approach to 
solve the problem of an in situ characterisation of the pulmonary de livery in-line 
with a patient. Section 1.4.2 presents a critical discussion of optical methods that 
have been successfully used for partic le-size measurements for in-line applications. 
Table 1.4. Commom methods for size analysis. 
Method Condition Teclmique On-line 
applications 
Scanning electron microscopy No 
Mi croscopy Wet or Dry Optical imaging; Automatic image 
analysers Yes 
Sieving Wet or Dry Wire woven; Micromesh screens No 
Sedimentation Wet or Dry; Micromerograph; Photo- and X-ray No Gravity sedimentation; ~ back scattering 
Wet Electrical resistance change No 
Sensing zones Wet or Dry Optical scattering; diffraction; 
obscuration Yes 
Dry Absorption; low-angle scattering; line 
X-ray method broadening No 
Wet ~ ray absorption 
Ultrasonic Wet Attenuation momentum transfer Yes 
1.4.2. Optical methods for in-line measurement 
The success of optical methods in particle size measurements is based on the 
amazing richness of the light interaction with particles and of the underl ying theory 
in which these phenomena were implicit. The light-particle interaction depends on 
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both the properties of the light such as wavelength and polarisation as we ll as the 
particle properties such as size, shape and refractive index. Maxwell equations that 
describe the interaction of light with solid matter are differential equations of the 
second order with mUltiple bowldary conditions and in many cases bulky numerical 
calculations are required to solve these equations precisely. High performance 
computers and huge memory capacity permit the solution of theoretical equations 
with multiple input parameters. Rapid evolution in light sources, photo-detectors and 
optical fibres make it also possible to reduce significantly the size of optical systems. 
Optical methods are widely used for online control and monitoring of the particle 
suspensions through industrial processes (beer industry; paint;) . Optical methods are 
also intensively used in the pharmaceutical industry as metrological tools for powder 
and particle teclmologies (for example Malvern and TSI pal1icle-sizing instruments) . 
Unfortunately, metrological methods require that only one or a few particles are 
present in the measurement volume at each measurement period and cmmot be 
applied on a whole, dynanlic, multi-particle aerosol released from an inhaler. 
Similarly, many industrial, online controlling methods m'e based either on a 
calibration by saIllples, when samples are measured by a metrology method and the 
online sensors are calibrated accordingly, or by extracting a sample from the 
production line into a bypass where a metrology routine can be appli ed. Neither of 
these approaches can work on the aerosol cloud in-line with a patient. In thi s sec tion 
we consider two optical methods that have been recently tried for measurements on 
the particle cloud released from an inhaler, and one robust industri al method for 
online control as generic prototypes for in-line characterization of the pulmonary 
drug delivery. 
lA.2.a. Particle imaging 
Shadows, two-dimensional (20 ) projections of illuminated pmticles, possess some 
limited, but sufficient, information about sizes and shapes of the particles and are 
often used for particle size measurements. These methods can be seen to consist of 
two parts, one concerned with imaging and the other with counting. Particle imaging 
techniques m'e easily applied for analysis of' flat' , 'stationary' particle samples using 
optical or scalUling electron microscopes. For dynaIllic online applications, where 
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the particle suspension fills a three-dimensional (3D) volwne the imaging process 
becomes problematic. The problems relate to the exposure time and the focusing 
depth of the imaging optics. The exposure time issue can be overcome by combining 
pulsed (strobe) lasers with high-speed cameras. The short-pulsed lasers enhance 
camera performance by illuminating a subject with ultra-short pulses of light. Image 
blur is eliminated , even for particles moving at high velocity. For exan1ple, the latest 
VisiLase system from Oxford Lasers achieves the effective exposure time of 25ns. 
In thi s case even the smallest droplets in the spray can be seen clearly - frozen in 
flight (Oxford Lasers, 2004). Counting methods are well establi shed for many 
metrological technologies and can fac ilitate effective counting of particle images 
according to their size. 
The principal drawback relates to the requirements on magnification, field of view 
and focusing depth. Higher magnification diminishes the fi eld of view and the 
focusing depth . For the purposes of evaluating on line the fract ion of the fine 
particles (size range from 0.5~m to 5~m) in the aeroso l (particle size range up to 
200~m) released from an inhaler, a metrological measurement through an imaging 
technique seems unfeas ible. The focusing depth issue can be overcome by forcing 
the aerosol cloud through a narrow passage creating a nearly 20 layer. In this case 
the effecti ve imaging and counting procedure can be established. But closely placed 
walls strongly affect the flow velocity and may introduce a sign ificant air-resistance 
and therefore carmot be considered as non-intrusive for measurements in-line with a 
patient. 
1.4.2.h. Laser diffraction 
After over 30 years of rapid development, laser diffraction has evolved into an 
extremely efficient method for the ana lysis of particle size distributions and become 
the dominant technique for optical particle sizing either in the labo ratory (off-line) or 
directly in the production process (puckhaber el al., 1999). While 'off-line 
application ' characteri ses different products, ' in-line application' integrates 
representative sampling and supplies the particle size info rmation immediately for 
continuous monitoring and automated process control. The applicable range 
according to 18013320 is 0.1 ~m to 3lfun. 
CHAPTER I 
27 
- -- - - -----------------------------------------, 
INTRODUCTION 
Figure 1.7 shows the classical Fourier arrangement, where dispersed primary 
particles interact with the light in the parallel laser beam. The diffraction patterns are 
collected on a higb.ly sensitive, semicircular, multi-element detector. With this input 
information, the particle size di stribution is calculated using the Fraunhofer 
approximation or Mie theory. Both methods require the fulfilment of some 
preconditions. The Mie theory describes accurately the light scattering by a smooth 
spherical particle and requires the complete knowledge of the complex refracti ve 
index. The Fraunhofer approximation assumes that the particle is opaque, and is 
much larger than the wavelength of the light employed (lS01332 defines thi s as 
being greater than 40.4. , i.e. 25 /lm when a He-Ne laser is used). Even small 
deviations from one of these requirements may result in dramatic changes in the 
calculated size distribution curve, as has been shown in severa l studies (e .g. Muller 
et al., 1996). 
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Figure 1.7. Optical set-up for generation of diffraction patterns consists of a laser, 
a beam expander (BE), Fourier lens and a multi-element photo-detector (D). S is a 
sample of dispersed particles. 
In the last few years, the LD technology has been developed as a very fast and 
highly reliable alternative to cascade impactor ana lysis in testing the aeroso l cloud 
released from an inhaler (de Boer et al., 2002; Holmes et al., 200 I). Authors 
critically compared the impactor analysis with the LD technique. They have found 
out the main theoretical limitations and drawbacks of the LD technique to be the 
following: I) measurement of geometrical instead of aerodynamic particle size; 2) 
volume distribution curves are calculated on the assumption that particles are 
spherical; 3) tbe apparent particle density and dynamic shape factors of drug 
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agglomerates are not known; 4) a choice between Mie and Fraunhofer theory has to 
be made and 5) evaluations of bimodal mixtures are not reliable. There is no real 
way to calibrate laser diffraction equipment; it can only be validated, to conflrm that 
it is performing to certain traceable standards. 
The use of laser diffraction metrology on-line is technically challenging because the 
measurement ideally requires a thin sample (to limit multiple scattering) of 
homogenously distributed particles illuminated by an expanded laser beam (a few 
square cm). The whole optical arrangement (source, beam optics, Fourier lens and 
detector) needs to be in air and such a configuration requires a significant volume 
(typically lL) of space. These conditions do not suit the use of laser diffraction 
metrology in the confines of an inhaler device in-line with a patient. 
1.4.3.c. Turbidity measurements 
For on-line monitoring of production processes , many industries such as water 
treatment plants, electricity plants and breweries employ a very simple and effective 
optical method: turbidity measurement (Sigri st, 1996; Allen, 1997.). Turbidity, 
cloudiness in fluids, is the reduction of clarity and transparency of a fluid sample due 
to the presence of suspended and colloidal matter such as clay, silt, soot and 
microorganisms. Turbidity is neither an absolute nor a metrological method. 
Turbidity measures neither particle size nor size distribution: for example, the 
presence of a small amount of the smaller particles can be confused with a much 
larger amount of the larger particles. Turbidity is an optical method and hence not 
subject to non-optical parameters like temperature, viscosity, pH or conductivity and 
is non-invasive to the production process. Despite its non-metrological nature, 
turbidity allows important management decisions to be made in real-time during 
industrial production, using an appropri ate calibration for a particular application. 
For example, in the water treatment industry, when raw water comes from the 
surface reservoir the turbidity measurement is used to control the amount of 
flocculant added at the processing stage. Natural phenomena like snowstorms and 
thunderstorms can render the water temporally unusable. In thi s case, turbidity 
control allows real-time deci sions to be taken as to whether raw water will be 
processed or di scarded (Sigrist, J996). The turbidity meters placed between the 
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settling tank and sand filters monitor the efficiency of the treatment for so lid 
impurity e limination (the flocculation process) . Turbidity measurements 
immediately after the sand filters are used fo r monitoring the actual filtration 
efficiency and for optimisation of the sand purging (the backwash) process (Sigrist, 
1996). 
In practice there are many different methods for turbidity acquisition ranging from 
the simplest Secchi depth to the optical turbidimeter. The Secchi disk method is 
often used to measure turbidity in the deep waters of lakes and rivers. The white, 20 
cm diameter disk is lowered into the water on a calibrated line and two readings of 
the depth are taken : 1) when the disk just di sappears from sight; and 2) when it 
becomes visible again during the raising. The average of these two distances is 
known as the Secchi depth and is used as a distinct measurement of turbid ity. 
3 
1 
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Figure 1.8. Principle of attenuati on turbidimeters, comprising a light source 
( I), a cuvette (2) fill ed with a suspension, and a photodetector (3) with a 
small angle aperture (a). 
An optical small-angle scheme measuring the attenuation of white light traversing 
the suspension in a forward directi on was recommended for assessment of the degree 
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of agglomeration in suspensions (Koglin , 1973). Figure 1.8 shows the principle of an 
attenuation turbidimeter. The parallel light beam (I) traverses the cuvette (2) filled 
with a suspension. The traversed light intensity is measured by a photo-detector (3) 
through a small-angle aperture (a). These turbidimeters (so called attenuation 
turbidimeters) are normally llsed fo r sllspensions when the so lid concentrati on is 
smaller than 0.1%. If the solid concentrati on is higher than 1 % , measurable 
transmissions are achieved only for very thin cuvettes. In thi s case, however, the 
scattered light intensity at a certain an gle can be measured and its chan ges refl ect the 
changes of agglomeration in the suspension (Koglin, 1977). This type of 
measurement, originally introduced for relative ly dense suspensions, was then 
modified and used for a wider range of turbidity values. Such devices are commonly 
referred as nephelometric turb idimeters and the turbidity value is defined as a ratio 
of the scattered and transmitted irradiances. 
Measurement units for turbidity have to be calibrated in relation to a standard sample 
due to the non-metrological nature of the technique. The Diatomaceous Earth and 
the Formazine SU5pension can be used as such standard san1ples. The nephelometric 
turbidity unit (NTU) is defined by the standard ISO 7027 (Water quality; 
Determinatio n of turbidity) and is often used in practice. 
The overwhelming advantages of the tmbidity method are its simplicity, non-
intrusive nature and ability to measme changes in the degree of the suspension 
agglomeration directly dming the monitoring of the process. 
1.5. Conclusions 
In sUl11ffiary, the object of the current investigation is a dynamically propagating 
particle cloud of a pulmonary drug formulation . The particle mass of a single dose is 
in the range of ten micro grams to two milligrams. The most important parameter is 
the inhalable part of particles, i.e. Fine Particle Dose (FP D), which is defined as the 
mass of drug particles in a single pulmonary dose with aerodynamic sizes in the 
range from 0.5 Ilm to 5 Ilm . The main objective is to develop a measurement 
teclmology allowing the efficiency of the pulmonary drug delivery to be 
characterised in-line with a patient. We call thi s technology VariDose and intend to 
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measure the delivered dose. The efficiency of the de livery directly relates to the 
degree of agglomeration in the aerosol released by an inhaler. 
The composition of the drug cloud during delivery is a complex function of the 
formulation, entrainment and di ssociation mechanisms as well as the detail s of the 
actuation system (human or mechanical). The teclUlology requirement fo r complete 
metrological assessment (in space and time) of this cloud during delivery is not 
currentl y available. The particle size distribution can vary throughout the cloud and 
the distribution of density and speeds throughout the cloud is such that a detai led 
tracking of particle positions and their sizes is not currently feasible. Instead of 
attempting such a metrological analysis, we use the macroscopic principles of optical 
absorption and scattering to generate signatures of the delivered cloud. A simple 
optical sensing technology simi lar to the turbidity measurement has been developed. 
It has the potential for actuation-by-acluation assessment of pulmonary drug delivery 
in-line with a patient. Data obtained in the specially des igned experiments are 
discussed to establish if this tecIulology can provide useful information about the 
released drug-cloud : its dose value and the fine particle fraction. 
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This model describes the aerosol cloud released by an inhaler and propagating 
tJu-ough a cylindrical tube for the purposes of measuring the optica l density of the 
cloud. The intensi ty of the light beam proceeding through an aerosol decreases due 
to the light scattered by patiicles . These losses due to scattering depend on aerosol 
properties atld are defined by the optical density of the aerosol. It is common 
knowledge that the air filled with rain droplets is transparent, while the fog may 
signifi cantl y obscure the view. In phys ics thi s fac t means that the vo lume fi ll ed with 
rain droplets has a lower optical density than if it is fill ed with a fog. To support thi s 
concept numeri ca l ca lculations have been made using the Mie theory for light 
scattering by spheres. 
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2.1. Model description 
The model qualitatively and quantitatively describes the interaction of a collimated 
light beam with a cloud of airborne particles released by an inhaler and moving in a 
direction perpendicular to the light propagation. 
2.1.1. Aims of the model 
The purpose of thi s model is to evaluate the design concept of the proposed 
technology (VariDose) for the pulmonary delivery assessment in-line with a patient. 
Using a well -establi shed theory of the interaction of light with small particles, the 
model investigates the following aspects: 
• The opti ca l obscuration of the collimated beam by a particle cloud; 
• The dependence on the light wave length ; 
• The sensitivity to the fine particles. 
The model also predicts the obscuration values for a given set of data measured by a 
conventional inerti al impaction device. For these purposes the model divides the 
particle population of the cloud into sub-species of different sizes and considers 
relative contributions from each particle type. 
2.1.2. Applicabil ity 
The model can be applied to any turbid medium. The main limit of applicability 
relates to the optical density of the mediwn. The limit arises from the assumptions 
made to calculate the reduction of the light intensity of the collimated beam tlu·ough 
the scattering by particles. To establi sh relationships between the light reduction and 
the microstructure of the aerosol , we calculate the extinction coefficient using the 
Mie theory and suggest a simple spatial di stribution of particles. 
The general Mie theory includes two main assumptions: 1) the light interact·ion is a 
single independent scattering and 2) the particles are spheres. In our model the single 
scattering requirement is furtber softened allowing a degree of multi -scattering. 
Particles in the measurement volume are considered independent; i.e. they are 
suffic iently far from each other that the electromagnetic fields within them do not 
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interact with each other. This assumption allows the addition of intensities from 
individual particles. Estimates have shown that a separation di stance of 3r (three 
times the particle radius) is a sufficient condition for independence (van der Hulst, 
1981). In the case of a mono-dispersion of spheres, to fulfil the independence 
criterion the volume concentration should not exceed 3% (C, = f m' ] 1(5,.)3). 
Single scatte ring means that the light scattered by an ind ividual partic le is regarded 
as being unaffected by other particles. In reality, each individual particle is 
illuminated by the direct light fro m a source and by the light, which has been 
scattered by other particles. For the single scattering, the multi-scattering component 
is assumed to be negligible in comparison to the light intensity directly incident upon 
the particle. Therefore, the si.ngle scattering would preva il if the particle 
concentration stays suffic ientl y low that the probability of the secondary scattering is 
low. In our model, when the extinction of a small collimated beam is considered, the 
requirements of single scattering can be re laxed allowing a degree of multi-
scattering. Indeed, in this case we need to compare the intensity of the light, which 
has been scattered by particles and does not reach the receivi ng detector, with the 
light intensity that reaches the detector through the subsequent scattering events. The 
probability fo r light re-entering the collimated beam is the probabi lity of secondary 
scattering l11ultiplied by the probability for sca ttering into the defined direc tion, and 
therefore, is significantly smaller than the probability of the second scattering. For 
particle concentrations, when the second scattering is noticeable, the intensity of the 
re-entered light can still stay negligible. An estimation of the particl e concentration 
limit for the model 's applicability illVolves many parameters: particles' s izes, the 
spatial di stribution, the length of the optical path and the properti es of the receiver. 
Therefo re it cannot be expressed in general form for such a dynamic and complex 
cloud as an aerosol cloud released by an inhaler. Instead, the concentration limit is 
studied on a few model clouds considering particles in the range of the pulmonary 
delivery: the fine particles and the coarse patticles with the size range from O.5pm to 
5pm aJld from 6 pm to IOOpm, respectivel y. 
The di stribution of particle species in the cloud is generally unknown and can be 
h.ighly inhomogeneous and continuously varying in time. A generic complexity of 
the cloud dynamics is simplified to the scope of the measurement method aJld is 
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modelled as a "snapshot signature" of the temporal variation of the optica l density at 
a given spatial location. For this conceptual study and fo r the transparency of the 
model conclusions the particle distribution is considered as being one-dimensional 
and fo llowing a homogeneous, Gaussian distri bution. 
The spheri ca l approximation fo r the particle shape is considered as reasonable for 
arbitrary-shaped particles (micronised dry powder formulations) and liquid droplets 
(p-MDI formulations) and is appl ied in the terms of the equivalent sphere theory 
(section 1.4. I .a). 
2.2. Particle distribution in a moving cloud 
An aerosol cloud released by an inhaler consists of a huge population of particles. 
These parti cles possess different shapes and sizes, might possess electrostatic charge 
and often fo rm agglomerates due to the adhes ion and Coulomb attraction. Many 
physical processes take place when parti cles and agglomerates enter the airflow. 
Most of these processes strongly depend on the particle s ize and initial condi tions 
such as velocity, temperature and time. 
Particles tend to reach the velocity of the fl ow through the viscos ity and drag action 
of the airflow. Generally, the small er particles react to variations of the fl ow rate 
quicker than the larger particles (Rudinger, 1980). On the other hand, large parti cles, 
such as agglomerates, catTier and excipient particles, usuall y possess a better 
fl owability and leave the powder bed easier, while the fine drug particles may stay in 
the powder bed longer due to their stronger adhes ion. 
In sprays released by p-MDls, the larger droplets possess the larger inertia atld more 
slowly relax down to the fl ow veloci ty, suggesting that the larger drop lets may be in 
the front part of the cloud. However, the so lvent evaporation from the droplets has a 
higher rate for the larger surface area atld at higher droplet velocity, and therefore 
may result in a rather unpredictable di stribution of particles through the aeroso l 
cloud. 
As a result in the most general case, the particle di stribution in the released cloud can 
be inhomogeneous atld continuously varying during the cloud propagation. 
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2.2.1. Spatial distribution 
An aeroso l cloud of a single-dose actuation moves with the airflow and occupies a 
limited vo lWlle of air. Most of the cloud parameters such as the cloud vol ume, the 
cloud veloci ty and the particle distribut ion are temporal variables. Figure 2. 1 shows 
schematicall y an aerosol cloud with two types of particles: two sub-clouds of mono-
dispersed particles. The volume concentration of particles is zero at the cloud 
boundaries and ri ses inside the cloud . 
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Figure 2.1. Schematic presentation of an aerosol cloud . 
For modelling purposes, the particle di stribution is signi ficant ly simplified to 
evaluate the main concepts of the technology. It is assumed that the particles are 
spread according to a Gaussian distri bution for each sub-cloud. Then, in the one-
dimensional approach, the vo lume concentration of airborne particles can be 
described by the fo llowing equation: 
C(7)-~C [(Zo-Z+t/!,)l] v - - i..J \'1 exp - 2 ' 
I.] 2s, 
[2 .\1 
where C"I are maximal values and S i are characteristic spreads of the particle 
distribution in the z-direction for each particle type, NI is the number of different 
types of particles, Z is the coordinate, Zo is the coordinate of the middle of the cloud 
and t/!, describes the relative positions of the different sub-clouds to thi s middle 
parameter. 
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There are straightforward relationships between the volume concentration C" , the 
particle number concentration N, the particle volume v pi of a single i-type particle 
and the particle number concentration n, fo r each particle type: 
N, N, C 
N(z) = Ln,(z) = L -'" , 
/= 1 /: \ Vpl 
12.21 
For convenience the fwiher general di scussion is carri ed out in terms of the vo lume 
concentration and equation [2.2] acts as a transition between the two methods of 
presentation. Note, that for a multi -species cloud the combined di stribution of 
airborne particles can be non-Gaussian due to the spati al shifts between the 
contributing distributions. 
2.2.2. Interpretation of the temporal and spatial variation 
In the proposed teclUlology a single sensor is placed perpendicular to the direction of 
propagation. The sensor gives information about particles within a small vo lume, 
which is defined by the sensor' s properties and the device geometry, and commonl y 
called the measurement volume. The sensor records, fo r example, a variation of the 
opt ical density while the aeroso l passes through the measurement vo lume. Each 
measurement data characteri ses particles within this measurement volume at the 
sensor position z" and is recorded as a temporal variable. Although such data 
present a temporal variation of optical measurements, in reality they include also the 
spatial vari ation of the aerosol. Indeed, for a tempora l sequence of measurements the 
indi vidual reading corresponds to the different parts of the aeroso l, which enter the 
measurement vo lume one-by-one. As a result, the sensor measurements depend 
strongly on the position of the sensor down the stream of the aerosol propagation. 
Therefore, in practice, to compare the cloud characterisation from di fferent 
experiments the position of the optica l sensor must be taken into consideration. It is 
also important to find an opti mal position for the sensor in each specific case, i.e. fo r 
a given combination of the drug formulation, the delivery device and the inhalation 
effort. An interpretation of the recorded data would include some elements of 
assumption and deduction and requ ires a thorough di scussion for an indi vidual 
experimental set-up. Generall y, in thi s thes is, the temporal data of a single sensor is 
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treated as "a snapshot" of the cloud in time, which accumulated both processes: the 
evolution of an aerosol cloud and the cloud propagation. 
For the modelling purposes of a dynamic cloud , we assume that a mUlti-species 
cloud is desc ribed by the Equation 2.1 and the cloud moves as a whole at a constant 
velocity Vd' neglecting poss ib le variations of the particle di stributi on due to the 
cloud evolution, e.g. de-agglomeration and agglomeration of some particles. As the 
fro nt edge of the cloud approaches the sensor position Zd the time scale is triggered 
and the temporal variation of the volume concentration can be described as fo llows: 
N, [(Z V I + '" )2 ] C (z r) = " C exp _ J - d ,/" 
v 11 ' ~ VI ? 2 
, .. I -&, 
{2.3 1 
2.3. Theo ry of light extinction 
The genera l mathematical description of the propagation and absorption o f light in a 
turbid medium is based on the photon transport theory (Chandrasekhar, 1960; 
Isltimaru 1978; van de Hu{st, 1980). Transport equations can rare ly be solved 
analyt ica ll y using microscopic properties of the medium; more often the solution is 
obtai ned by introducing macroscopic characteri sation for the medium. 
The main purposes of our model are to find out the role of the fine particles in the 
opti cal density of an aerosol and to evaluate if the transmi ttance of the co llimated 
light beam characterises the dose of the fine pmiicles. Therefore the microscopic 
properties are important for our model. The phys ical model is simplified to the level 
where the microstructure of the cloud can be eva luated. A fundam ental so lution can 
be achieved in the linear limit using the Lambert-Beer law and applying the Mie 
theory to calculate the extinction coefficient. 
2.3.1. La mbert-Beer law 
A linear transport equation is a differential equation of the fi rst order and describes 
linear losses of the light intensity through the scattering: 
dl 
-=-yl 
dz 
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where I is the radiation intensity, z is the space coordinate in the direction of 
propagation and y is the so-called extinction coefficient. The so lution of thi s 
equation is usually referred to as the Lambert-Beer law, which describes the 
exponential decay of the radiation intensity due to absorption and scattering in the 
homogeneous medium: 
I = I" exp( -yL) [2 .5] 
where ID is the intensity of the incident light and L is the length of the path in the 
medium. The essential assumptions of the Lambert-Beer law are the homogeneity of 
the medium, i.e . the extinction coefficient does not depend on the space coordinate, 
and that the ex tinction coefficient is independent of the light intensity . The intensity 
independence requires that the concentration of the scattering/absorbing centres in 
the medium is not too high, C<O.O 1 M, (Skoog el al. , 1997). 
The Lambert-Beer law has been successfully used in practice, for example In 
analytical chemistry (Skoog el al. , 1997). Indeed, measuring the transmiss ion of 
light for different thicknesses (L) of a homogeneous medium enables the 
experimental value of tJ1e extinction coefficient to be deduced . Then it is possible to 
determine the concentration of absorbing centres in the solution via measuring the 
light transmittance (T = J I I" ) and using a working curve of transmittance versus 
concentration derived from standards. 
Unfortunately, for aerosol applications, creating standards IS a rather challeng ing 
task due to the uncontrollable nature of the agglomeration/de-agglomeration 
processes. For this reason we assume that particles are spheres and calculate the 
extinction coefficient using Mie theory. 
2.3.2. Mie theory method 
The scattering of light by particles cannot be treated in a general way, other than by 
the formal so lution of Maxwell's equations with the appropriate boundary 
conditions. The problem of light scattering by homogeneous spheres in single 
scattering approximation was rigorously investigated in the second half of 19th 
century. The genera l solution was published by Gustav Mie (Mie, 1908) and is 
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usuall y referred to as the Mie theory. The scattering of light by homogeneous 
spherical particles composed of isotropic materials can be computed readily using 
the conventional Mie theory or its modification . Here we introduced basic fnrmu las 
and values used in the model , following notations and mathematical equations 
developed by van de Hulst (van de Hulst, J 98 1). 
2.3.2.0. Mie coefficients 
The Mie solution gives the fie lds of the electromagneti c wave at any poi nt inside and 
outside the parti cle. In principle it is possible to calculate the light intensi ty at any 
point of the space. In order to simplify the notati on, consider the outside medium to 
be a vacuum (1112 = J) and the material of the sphere to have a refractive index m , 
fo llowing van de HuJst' s notations (van de Hulst, J 98 1). General so lutions are 
expressed in the Mie coefficients 0 " and b" , which are calculated through the 
Riccati-Bessel functi ons VI", X" ' S" and the derivatives of these functions (denoted 
by primes): 
a = If 'n (Y)lfn(x)-mlf"(Y)If ',, (x) 
" If'" (yK"(x) -m lf,,(yK',, (x) 
b = m 1(/ '" (Y)If"(x)-If,,(Y)V/ ',, (x) 
" m If '" (yK" (x) -If "(yK',, (x) 
[2.61 
The parameter n is an integer from I to infinity. The arguments x and y depend on 
the radius of the sphere r and the wavelength of the light 2: 
2n,. 
x=-
2 
m2nl' y=--
2 
[2.71 
The parameter x, which equals the ratio of the circumfe rence of the sphere to the 
wavelength, is the most important parameter here and sometimes is cited as the size 
parameter. 
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2.3.2.h. Extinction coefficient 
For a light beam propagating through vacuum (ni, = I), which contains N mono-
di spersed spheres per unit volume, according to Mie theory, the extincti on 
coefficien t r is computed from the fo llowing formula: 
12.81 
independently of the polarisation state of the incident light. The value of the 
extinction efficiency Q"'t depends on the radius of spheres, the refractive index (111) 
of the sphere material and the wave length of light (x = 2w/ A.) and is expressed in 
the Mie coefficients as follows: 
2 ~ 
Q,." = -, L)217 + 1)91e[a" (x, 111) + b,,(x, /11)] 
X I/ .. t 
12.91 
The symbol me denotes the mathematica l operation of taking the rea l part of the 
complex number. 
According to many authors (van de Hulst, 1981 ; Bohren et ai, 1983) the scattered 
field series are uniformly convergent and, therefore, the infinite sum can be 
terminated after a finite number of terms, 17 = l7e . The resulting truncation error can 
be made arbitrary small by taking strfficient terms. An extensive study of thi s issue, 
conducted by Wiscombe (Wiscombe, 1980), suggests a finite number which depends 
on the s ize argument x : 
17e =x+4.05Vx+ 2 12.101 
It has been shown (Barnett, 2000) tbat the Wiscombe criterion indicates the 
convergence point accurately for a range of the particle sizes (10-' < x < I OJ) and a 
selection of refractive indexes ( 1.1 < 111 < 5). This range of paran1eters are covered 
the entire range of particles, which are used in the pulmonary drug deli ve ry and are 
the subject of thi s thesis. Therefore, we can apply the Wiscombe criterion in o ur 
ca lculati ons. 
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For a medium, which contains multiple particles of diffe rent radii , and if there are 
N(r)dr particles of radii between rand r+dr per unit vo llime, the extinc tion 
coeffi cient includes contributions from all particles and is expressed by the 
foll owing integral equation: 
~ 
r = J QUI (r , ,1.)N(r )m·2dr \2.11 \ 
o 
In our stud y we consider onl y a discrete number of different paI1icles, there fore thi s 
integral equation is simplified to the sum : 
N, 
y= LQw (/j,,,1,)N;m;2 \2.12J 
;=1 
Mie theory considers individual particles and therefore it is convenient to operate in 
particle numbers. On the other hand, fo r the dose cloud it is convenient to consider 
the volume concentration of the airborne materia l C, and fractions of each particle 
type (equation (2.7)). The conversion relati on between the parti cle number per unit 
vo lume N and the volume concentration C,. includes the vo lume of a single parti cle 
and has the following form, supposing particles are spheres of the di ameter d = 21' : 
N= 6C. 
7[(/3 
for mono and poly dispersed med ia, respectively. 
\2.131 
[2.14) 
Applying the LambeI1-Beer law for the light propagation (equation (2.5 )) and Mie 
theory for the extinction coeffi cient (equations (2.9], (2. 12] and (2. 14)), we can 
calcul ate tJle light transmi ttance through a medium using its optical properties and 
mi crostructure (equati on (2.3]). For all aeroso l cloud containing N, types of spheres 
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(diameters d,) and passing at a constant velocity Vd the optica l sensor, which is 
located at the position z", the light transmittance takes the foll owing form: 
12.151 
2.4. Light extinction by a cloud of particles 
Tlus section 2.4 presents calculation results for some bas ic situations, whi ch 
illustrate the specific role of the fine particles for the technology concept. Tlu·ee 
types of cloud are investiga ted: 
• Stati onary mono-dispersed clouds show the dependence of light extinction on 
particle sizes and light wavelengths. 
• The example of a two-species cloud interprets the relative contributions of 
di fferent components to the light obscuration and its temporal profil e. 
• The example of a nine-species cloud is considered fo r the purposes to 
compare the optical data with conventional inertia l impacti on data (NOI) and 
to discuss issues related to the vo lume concentrati on of airborne material and 
panicle sizes. 
We consider light with the wave length range from 400run to 900nm, assuming that 
this range is less affected by the material absorption (electron excitations and 
molecular vibrations). In all further calculations the refracti ve index of pan icles is a 
real value and equal to 1.25 (being typical of drug particles). 
2.4.1. Stationary mono-dispersed clouds 
Consider the collimated beam of a monoclu-omatic li ght source illuminating an 
aerosol cloud that consists of mono-dispersed spheres. The particles are 
homogenously distributed in the cloud and possess a volume concentration of IOppm 
(parts per million) . The cloud thickness in the transmission directi on is I cm. The 
light transmittance through this cloud is calculated by equations [2.8) and [2. 13) for 
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a single type of parti cles (N, = 1). The extinction coeffi cient and the Mie 
coeffi cients are calculated using the MatLab code developed by D.M. Barnett 
(Barnett, 2000). Figure 2 .2 shows the light transmittance as a function of the particle 
diameter at three light-wavelengths. 
This dependence shows that for a fi xed volume concentration of the airborne drug 
material, the optical attenuation is highest for pa11icles of a certain di ameter, the 
va lue of which slightly varies around ll-lm with the light wavelength. For the 
pulmonary de li very the most important particles (the fine particles, section 1.3.3.a) 
are approximately in the s ize range from 0.5 1-1111 to 51-1m . It seems that the light 
wavelength of 650nm is a good choice fo r optical sensing of the pulmonary deli very 
due to a high sensitiv ity to the fine pm1icles and a negligible absorpti on in the case 
of typical drug formulations. For a multi-spec ies clo ud the spectral op timum of the 
max imal " sensitivity" may depend on formulation and aerosol properti es and has to 
be establi shed experimentally for a given set of a drug formulation and a deli very 
dev ice. 
Figure 2.2. Transmittance as a function of the particle diameter for three 
different wavelengths of light 
Note that these results are based on many assumptions (which have been made to 
simplify the calculation) and, therefore, have only qualitati ve viability. One of the 
areas where significant discrepancies can appear is the drug fo rmulations based on 
CI-IAPTER2 45 
Mode] 
relatively large and porous particles of small aerodynam ic sizes. In this case a much 
more complex model for light ex tinction by particles must be employed. 
2.4.2. A dynamic cloud containing two species 
A key feature of the technology implementation that we propose is that it is sensiti ve 
to the dynamics of the cloud, not onl y in terms of its density but also in terms of its 
homogeneity. In making the hypothesis that the distribution of part icles in the drug 
cloud is not homogeneous, it is also implied that the degree of inhomogeneity will 
characterise the actuation, formu lation, device and user. One way in which the c loud 
might be inhomogeneous is in terms of the spatial distribution of particle size and 
thi s might be a consequence of the dissociation and entrairu11ent mechanism of cloud 
format ion. To illustrate the effect of combini.ng particles in a cloud, consider a 
simple case in which the cloud is composed of two types of spheres: d, = Ipm and 
d, = 6pm . For the purposes of il lustration , assume that both partic le clouds fol low a 
Gaussian type of distribut ion in space and are displaced from each other. If the 
combined cloud moves as a whole with a velocity Vel' then the temporal variation of 
the vo lume concentration for each species is described by the equation [2.3] and 
takes the fo llowing fo rms: 
12.1 6] 
12.17] 
where C" = I Oppm is the maximal vo lume concentrati on, f:, IS the standard 
deviation for each distribution and z" is the spatial coord inate of the sensor position 
chosen along the cloud propagation axis, the time ori gin (I = 0) is when the fro nt 
edge of the cloud approaches the sensor pos ition z". A phase difference ~ reOects 
the spatia l displacement between the two clouds. The particle distributions are 
graphicall y presented in Figure 2.3 by the dotted and dashed lines, for particles of 
I flm and 6flm diameters respectively. 
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For this combined cloud we calculate the optical obscuration as a function of time 
Obs(/) = 100% [1 - 1(/)/ 1. ) at the light wavelength of 650nm. The transmittance is 
calculated using equations [2 .1 9) supposing that for each moment of time there are 
two particle components controlled by equations [2.20) and [2.21]' The solid line at 
the fi gure 2.3 presents the obscuration profil e of the combined cloud. At the same 
vo lume concentrations, at the max imums of individual di sb'ibutions, the obscuration 
is 25% and 4% for particles of the I ~lIn and 6~lm diameter, respectively. 
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Figure 2.3. The model calculation provides the obscuration of a dynamic 
cloud (the solid line), propagating with velocity of 3 m/sec and contain ing 
two particle types . The dashed and dotted lines present the dynamic 
volume concentrations for the 6~lm spheres and the 1,lm spheres, 
respectively. 
Clearly the obscuration measurement does not resolve the complex issue between 
the particle volume concentration and the particle size distribution, however, it may 
be able to detect the presence of the fUle p81iicles. Indeed, thi s example shows that 
the cloud with maximal concentration of 10ppm induces a light obscuration of 
approximately 4%, if particles are spheres of 6!lm diameter, while for the l!lm 
spheres the obscuration rises to over 25%. 
There are two main conclusions from this simple example. Firstly, for the same mass 
of the drug formulation the higher obscuration takes place if more particles de-
agglomerate to sizes of around 1 !lm. Therefore, the optical obscuration can be a 
measure of the fine particle dose of 811 individual actuation, but onl y if the total 
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doses have the same load of the same drug form ulation. Secondly, although particles 
larger than 6pm, contribute significant ly less to the obscuration, their effect is not 
negligible. Therefore, a non-Oaussian profile of the obscuration can be explained 
either by a non-Gauss ian spatial di stribution of the fme particles or by a spatial 
separation of the cloud species, which may individually follow a Gauss ian 
d istri bution. 
This experiment shows that the interpretation of optical data requires a cautious and 
thorough ana lysis in each specific application. In the next section we cons ider one 
example of such an interpretation in relation to NO l measurements. 
2.4.3. Multi-species clouds and NGI measurements 
For fUli her investi gation of the role of the particle-size distribution on the optica l 
obscuration we consider a nine-species aerosol, which estab li shes a direct 
relationship with the data obtained by the Nex t Generation Pharmaceutica l [mpactor. 
The performance of a pulmonary drug delivery system is normall y eva luated by 
means of a multi-stage cascade impaction system (see section 1.3.3). The Next 
Generation Pharmaceutical Impactor (NG I) is the most advanced device for testi ng 
the pulmomu'y delivery systems (Asking el al., 2003). The NG ! system consists of 
nine impaction stages. Each stage collects particles of the specified aerodynamic 
sizes and is characteri sed by the median of the diameter distribution (0 50) . The 
median parameters for the NGI system are ranged from 0. 13 pm to I O~lm: I O~lm , 
7.8~lm , 4.6pm, 2.7~lm, 1.6pm, 0.9~lm, 0.5~lm , 0.3~lm and 0. 1 3 ~lm . The result of the 
NG! meaSlU'ement is the distribution of the drug mass over particle aerodynamic-
sizes accordingly to the dmg mass collected on each stage. 
There is no attempt to so lve precisely the reverse problem in thi s complex case due 
to the ambiguity of the optical responses (see section 2.4.2). Instead, the model 
describes the relative contribution of different species to the opti cal obscuration by 
an aerosol cloud with the particular specified properties and discusses the issues of 
the aerosol density (the vo lume concentration of the airborne material) and the fine 
parti cle dose. 
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2.4.3.a. Model equations andfurther assumptions 
The NGI data present the mean values of a whole aeroso l cloud; and very often the 
averaging process takes place not only for a single cloud, but also over several 
consecutive actuations (often 5) due to the existing limits for the drug detection. 
Therefore, the NGI data provide no temporal variations of the aerosol cloud. On the 
contrary, the proposed optical technology is intended to characterise a single 
actuation and an inll0mogeneity in a single cloud. For illustTati ve purposes, we 
introduce, as an example, a Gaussian di stribution for all sub-clouds and for the cloud 
as a whole. Equation [2.1] is modified for the nine-species cloud, where £, = 8 0 and 
1jJ, = 0 are the same for all sub-clouds: 
12.181 
_(, [(Z,,-Z)' ] CAz, d,) - . ,C, .• exp - , ' 
28. 
12.191 
where C, .• is a parameter for the vo lume concentration and;; are parameters for the 
vo lume fract ion of different species. The volWlle fractions are defined via the mass 
rat ios;; = 117/ tl17i and assumed constant throughout the entire cloud. 
Us ing equations [2.12], [2.9] , [2.18] and [2.19] the extinction coefficient and 
efficiency can be expressed in the fo llowing: 
(A J; d ) = 3A' C" f j,q, CA, d,) r , 1.. .9' 1...9 2 L. d' 
7r i:: 1 I 
12.201 
" q,CA,d,) = 2)2n+ 1)9Ie[a,,(x,CA,d,))+ b" (x,CA,d,))] 12.211 
11",1 
where C, is the total volW11e concentration of the drug formulation and d, are the 
median particle diameters for the NGI stages. Note that the extinction coefficient is 
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strongly dependent on the particl e Sizes, the particle fractions and the light 
wavelength . 
The purpose of the model is to investi gate the effect of the volume concentration and 
the fine particle fraction on the optical extinction. Therefore, the volume 
concentration is treated as a parameter with a wide range of va lues. In rea lity the 
vo lume concentration can be estimated from the experimental data: 
9 Lm, 
(c .. ) =_,,=;0'_ 12.221 
p I F(I)dl 
" 
where 117, are the drug masses at the NGI stages, p is the materi a l density of the 
drug, F(t) is the flow rate and {, and 12 are the times of the cloud observation. 
Aspects of the fl ow measurement and specifics of the fl ow interaction with the drug 
fo rmulation are irrelevant to the proof of the teclmology concept and exceed the 
scope of tlus thes is. 
The further calculations (sections 2.3.3.b and 2.3.3 .c) are performed using the data of 
one rea l measurement by NG l. The drug formulation, for thi s data, is a mixture of 
salbutamol sul phate (40%), nlicronised thro ugh a mill ing process, and Respi tose 
(60%) with a particle range from 45~lm to 90J.lm . Fi ve consecutive actuations were 
analysed as one averaged set of NGI data. Table 2. 1 shows the NGI data, the mean 
values of the drug mass collected on each stage. The metered dose of the actuation is 
263 ~lg, the mean emitted dose is 232.04J.lg and the fine particl e dose is 226. 1 9~lg . 
The fine particl e dose (FPO) equals the sum of the stages from 2 to 6, inclusive, for 
the further definitions please refer to section 1.3.3 .a. Note that lactose particles 
contri bute neither to the chemical analysis of NGI measurements nor to the optica l 
measurements. The extinction coeffi cient fo r such large particles as Respitose 
powder is much smaller than for the microni sed drug parti cles. Therefore, the 
Respitose particles introduce only a negligible obscuration (thi s has been confirmed 
by the experimental data, presented in Chapter 4). 
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Table 2.1. NGI data on particle size dist,·ibution. 
Throat Stage I Stage 2 Stage 3 Stage 4 Stage 5 Stage 6 Stage 7 Fi It e r 
0 50 , > 10 7.8 4.6 2.7 1.6 0.9 0.5 0.3 0.13 
[,llll] 
Rea l cloud , 0.72 0.72 5.36 39.74 94.56 62.98 10.02 1.64 16.30 
[fig] 
Hypothetical 135.0 135.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 
cloud, [,lg) 
2.4.3.h. COf1cef1tratiof1 issue 
The issue of the concentration range, at which the VariDose technology can be 
successfull y applied for the purposes of assessing the pulmonary de livery, is 
discussed using two examples of the drug cloud, presented in Table 2. 1 : the real and 
hypothetical clouds. 
Using equations [2.20] and [2.2 1] we calculate the opt ical obscuration 
Obs = 100%[1- 1/10 ] = 100%[1 - exp(-yL) ] assuming different values of the vo lume 
concentration (C. ) and keepi ng the species ratios at a constant. In the other words, 
we calculate the obscuration as the airborne mass of particles increases keeping the 
particle fractions J, (i = 1,2, ... 9) constant. The L parameter equals 25mm and 
describes the geometry of the optical sensor (p lease refer to Chapter 3). 
Figure 2.4 shows the monotonic increase of the optical obscuration up to a complete 
obscuration. [n reality the complete obscuration does not happen because the model 
assumptions are broken at sufficiently hi gh optical density. Indeed, at high particle 
concentrations the collimated beam transforms into a diffuse illumination of the 
turbid medium due to a significant multi-scattering. In that case the light propagation 
is normally described through a diffusion theory (lshimaru, 1978; Cheong et al., 
1990), and the transmitted intensity would be determined via the diffusion 
coefficient ratJler than scattering. One can see tJlat tJle concentration range also 
depends on the light wavelength. The figure 2.4 shows that for this given particle-
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sIze distribution the blue light (A. = 450nm) would be more appropriate for 
assessment of the lower doses, whi le the near infrared li ght (A. = 800nm) would be 
bener for the slightly higher doses. 
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Figure 2.4. Optical obscuration as a function of the volume concentration . 
Tbe given example of the real cloud is characteri sed with an extremely high fine 
particle fraction of 94%. For such drug fo rmulations (the solid lines on Figure 2.4) 
the vo lume concentration of 20ppm probably wo uld be too high for the model 
assumptions. For a different drug formulation or a different delivery device, when 
the fine particle fraction can be significantly lower, the concentration lim it could be 
higher. For comparison, the dashed lines present the optical obscuration for a cloud 
containing 8% of the fine par1icles and the same delivered dose (the hypothetical 
cloud in Table 2.1 ). Indeed, for the same obscuration level (for example 40%) the 
vo lume concentration increases by 5 times: from 8ppm to 40ppm fo r tbe light 
wave leng1h of 650nm. 
This numerical investigation shows that the volume concentration of 20ppm may be 
considered as the applicabi li ty limit for the VariDose technology, which is aimed to 
produce clouds with a substantial amo unt of fine par1icles. Although, if the drug 
formulation fai ls to de-agglomerate, the obscuration would be low and dose 
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assessment could be perfo rmed on a cloud with the vo lume concentration of the 
airborne particles up to 100ppm (0.01 %). For applications where a dif ferent range of 
particle sizes has to be assessed, this model can be used to eva luate the concentration 
limit of the method's applicability. 
The other conclusion is that at a given vo lume concentration the obscurati on va lue 
measures the dispers ion of the drug fo rmulation: the higher the obscuration is, the 
higher is the fi ne particle fraction. For example, at the vo lume concentration of 
I Oppm and the light wavelength of 650nm the obscuration of 48% would correspond 
to the FPF of 94%, while the obscuration of 12% would indicate a poor de-
agglomeration with the FPF of 8%. Therefo re, fo r the given metered dose of the drug 
formulation the optical obscuration can characteri se the [me particle fraction in the 
released aerosol, which is the most important and highl y unpredictable parameter in 
the pulmonary delivery. 
2.4.3. c. A dynamic cloud find fine particles 
In th is section we investi gate the optical obscuration of a moving cloud and the 
' signature' of the fine particles on the obscuration profi le. We conti nue to consider 
nine types of particles relevant to NGI data (refer to Table 2. 1). These parti cles are 
divided into tlu'ee groups, which present three types of the particle behav iour ill the 
pulmonary delivery: 
I . The finest particles with aerodynamic diameters of 0.3pm and 0. 13pm are 
co llected on stage 7 and the final filter of the NGI system. They are normall y 
thought of as being exhaled from the lung and therefore not contributing to 
the lung deposition. 
2. The fine particles with an aerodynamic diameter between 0.5pm and 5 pm 
are co llected on four stages (from stage 2 to stage 6). They are usually 
regarded as being penetrated into the deep lung and considered as the lung 
deposition dose (the fi ne particle dose FPD). 
3. The coarse particles with aerodynamic diameters of 7.8pm and 10pm are 
collected on stage I and the throat, and are normally related to the 
oropharynx deposition. 
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To separate the obscuration contribution from these three groups of particles, we 
introduce a canonical model experiment: 
• The total volume concentration, the sum of all particles C;oWI, rises and fa ll s 
sharply, and stays constant at 5ppm throughout the enti re cloud fo rm ing a 
step-f"llllction (the so lid line on Figure 2.5.a). 
• The fine particles have a one-dimensional Gauss ian di stribution with the 
max imum of 5ppm and this extends throughout the entire cloud, C:.·"· (z) (the 
dashed line on Figure 2.5 .a). Partial fract ions of different particles are kept 
constant over the distribution /, = m,lt In, for the indexes from 3 to 7 
,-3 
(using as an example the data fro m Table 2.1). 
• The fi nest parti cles are in the forward part of the cloud. The vo lume 
concentration of these particles, C;:" (the dotted line on Figure 2.5 .a), is 
adjusted so that the sum with the fi ne parti cles produces the constant tota l 
value of 5ppm, C,~p (z) = C;",ol -C:·"· (z) . Partial fractions of two components 
are /, = m/tsm, fo r indexes 8 and 9 (using the data from Table 2.1). 
• The coarse particles are in the rear part of the cloud. The volume 
concentration, Cl' C, (the dashed-dotted line on Figure 2.5.a), IS 
complementing the fine particle distribution with the total particle 
concentration constant, C~/'(z) = C:.",ol -C,~"p(z). Masses from stage I and the 
throat (Table 2.1) define the parti al fractions of these two components, 
/, = m.jt, m, , as an example. 
• The entire cloud is moving at a constant velocity of 3mJsec. 
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Figure 2.5. Light obscuration calculated for a canonical model experiment. 
The aerosol contains three groups of particles (finest, fine and coarse) and 
moves at a constant velocity through the observation plane: (a) presents 
distributions of the volume concentration for the particle groups; (b) 
compares the obscuration profiles of the total cloud , the sub-cloud of fine 
particles and the sub-cloud of mono-dispersed spheres of 1 .6~m diameter. 
Figure 2.5.a presents the profile of the vo lume concentration (the so lid line) and 
locations of three sub-clouds: the fi nest particles (the dotted ltne), the fine particles 
(the dashed line) and the largest particles (the dashed-dotted line). The space 
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coord inate is converted to the time using the cloud velocity of 3m/sec to allow a 
direct comparison with the temporal profil e of the obscuration (Figure 2.S. b). 
Figure 2.S.b shows the obscuration profile for thjs cloud (the so lid line), which is 
calculated exploiting the independent scattering by all particles and using equat ions 
[2.20] and [2.2 1] at the light wavelength of 6S0nm. For compari son, the light 
obscuration has been al so calculated fo r the further two clouds. One of them contains 
onl y the fine parti cles and has the same particle di stri bution as in the sub-cloud of 
the fine particles in the multi-species cloud (the dashed line on Figure 2.S.b) . This 
curve presents the contri bution of the fi ne particl es into the cloud obscura tion. 
Another cloud contains only mono-dispersed spheres of 1.6 ~un diameter and the 
particle di stribution is identical to the sub-cloud of thi s type of particles in the multi-
species cloud (the dotted line on Figure 2.S .b). This curve shows the contribution of 
these most effi cient scatterers to the li ght obscurati on of the entire cloud. 
As one can see on Fi gure 2.S. b, at the vo lume concentration of Sppm di ffe rent 
parti cles obscure di fferent amounts of the light intensity: for the finest partic les it is 
2.3%, for the coarse particles it is 4.7% and for the fi ne particle it is a mass ive 3 1 %. 
When half of the airbo rne matter is fi ne particles and the other half is coarse 
particles, i.e. a fine particle fraction (FPF) of SO%, the cloud obscuration is 19%, the 
majority of which is caused by the fi ne partic les (17%, the dashed line). For the 
cloud of finest and fine particles with FPF of SO% the resul ts are similar with 18% 
and 17%, respecti vely. 
Therefore, for actuations with a good particle di spersion, when the FPF exceeds SO% 
(p lease refer to the middle of the cloud on Figure 2.S), we can expect that the fine 
par ticles mainly cause the light obscuration; and the obscuration value can be 
regarded as a measure of the fine parti cle dose (FrO). 
For actuations with a poor parti cle di spersion, when the FPF is less than 6% (please 
refer to the tail of the cloud), the light obscuration is mainly caused by the coarse 
particles; and the obscuration value characterises the emitted dose (EO) rather than 
the FPO. 
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For the majority of other cases, when the FPF is moderate, around 20%, the 
interpretation of obscuration data is not straightforward and requires a detai led 
analysis. The main steps of such analys is can be as following: 
I. Estimate the volume of airbollle matter by di viding the mass of the drug 
formul ation on its material density. 
2. Estimate the cloud volume by integrating the flow rate of the inhalation over 
the duration of the obscuration profi le. 
3. Then, estimate possible value of the volume concentration of the airborne 
matter by dividing the estimated volume of airborne matter on the estimated 
cloud vo lume (also refer to Equation [2.22]) . 
4. Calculate the light obscuration for diffe rent types of particles at this vo lume 
concentration using our model and compare the model values with the 
measured obscw·ation. 
5. Due to the large diffe rence in the obscuration efficiency fo r fine and other 
palticles, the presence/absence of the fine particles can be established for 
each particular case, while a general relationship between the obscurat ion 
val ue and the FPD for any drug cloud is restricted by the optical ambiguity. 
2.5. Summary 
The developed model calculates the light obscuration of the collimated beam 
assuming an independent scattering by ai rborne particles. The cloud content is 
presented as an ensemble of di fferent groups of particles, relative to particle s izes. 
Using the Beer-Lambert law fo r light extinction and the Mie theory for light 
scattering, the model ca lculated the light obscuration using a spherical 
approx imation for the particle shape. The model shows that a relatively simple 
optical sensing may provide valuable information about the particle de-
agglomeration in the emitted aeroso l, without attempting to solve a precise 
metrological problem. It has been shown that the fine palticles, which are able to 
reach the deep lung and are the main objective in the pulmonary drug delivery, 
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possess the highest scattering efficiency in comparison to the other particle sizes at 
the wavelength range from 450nm to 800nm. 
The model proved the main concept of the VariDose technology showing a selective 
sensitivity of the transmitted light to the fine particle fraction in the turbid medium. 
[t also shows that temporal variation of the transmi tted intensity of a collimated light 
beam may provide unique information on the cloud inhomogeneity, measured 
directly on an emitted dose and in-line with a patient. The presence of the fine 
particles is characterised by a higher optical obscuration, supposing the amount of 
the drug formulation is metered and is sufficiently low. The higher the fine particle 
fraction is, the higher is the obscuration. Therefore, it is may be possible to calibrate 
the sensor to measure the fine particle dose for a particular drug formulation. Such a 
calibration cmve may enable a fast and robust assessment of the pulmonary delivery 
systems without using metrological methods, which are normally invasive, time-
consuming and not suitable for use in-line with a patient. 
Using a prototype device and specially designed experiments the model conclusions 
are examined empirically and results are presented in Chapter 4. 
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Chapter 3 
Method for in-line Assessment 
This chapter describes a prototype dev ice, data acquisition and analytical routine for 
effi cacy characterisation of the pulmonary delivery in-line with a patient. Thi s 
technology is called VariDose. Its aim is to measure the fine particle dose during an 
actual pulmonary delivery and to evaluate the dose variation due to ambient 
conditions. At this early stage of the teclUlology development, the major objective 
was to prove the concept rather than to optimise the measure ment parameters. A 
specific technica l arrangement and analysis method have been deve loped and tested. 
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3.1. Prototype device. 
The model developed in Chapter 2 shows that the light attenuation across the aerosol 
cloud strongly depends on the aerosol palticles. It has been shown that not only 
optical properties such as refracti ve index and light wavelength contro l the light 
attenuation, but also the particle sizes and the particle distribution over the aerosol 
cloud. There is a strong indication that the measure of light attenuation can provide a 
signature of the particle content in the cloud. The simplest arrangement to measure 
the light attenuation requires a collimated beam of light and a light detector in the 
line-of-s ight position. This pair of the light source and detector will be referred to as 
a ' sensor module ' or a 'sensor'. 
One of the possible positions of the sensor is perpendicularly to the direction o r the 
cloud propagation. Consider an aerosol, discharged from an inhaler. The aerosol 
cloud is propagating from an inhaler to the respiratory system of a patient through a 
designated air-path. In this case the light attenuation is determined by particles 
within the illuminated volume of the moving aerosol. The value of light attenuation 
changes as the particle content of the illuminated vo lume changes due to the aeroso l 
propagation. The temporal profile of attenuation contains a signature of the cloud 
dynamics. This information is rather limited and unable to reso lve the complexity of 
particle distribution in space and time, however, it may sti ll characterise the de-
agglomeration of the drug formulation (see section 2 .1 ). 
The in-line requirement puts dimensional restri ctions on an optica l attenuation 
device: I) the air-resistance of the device has to be much smaller than the inhaler' s 
air-resistance; and 2) the device volume has to be much lower than the inspiration 
vo lume of a patient (usually 2L or 3L). A standard mouthpiece, a cylind ri cal tube of 
25mm diameter and 65mm long, commonly used in cLin ical tri als of inhalers, is a 
good mechanical base for the proposed teclmology. The air velocity through thi s 
tube is near 3m/sec at the flow rate of60Llmin. When an aerosol propagates through 
such a tube, the optical density increases from zero (no cloud) to the maximum value 
and returns to a small value, which results from a particle deposit on the tube (the 
wall residue) . The average vo lumetri c density of particles in a cloud is expected to 
be less than 1% . 
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3.1.1 Essential equipment 
Figure 3. 1 sbows the essential components of the VariDose technology. A patient, or 
a breathing simulating machine, or a vacuum pump can provide airflow. The airflow 
actuates an inhaler device creating the particle cloud. The cloud propagates through 
a glass tube and the sensor module makes measurements at a given distance from the 
inhaler's mouthpiece. All connections in the fl ow path are airtight and the tube is 
screened from the ambient light. 
Spectra meter 
Inhaler Flow 
Light Source 
Figure 3.1. Schematic diagram for optical characterisation of the pulmonary 
drug delivery. 
The collimated light beam is formed by a SELFOC ® fib re collimator and Ocean 
Optics tungsten halogen light sow'ce (bulb colour temperature 3, 1000K). The 
SELFOC ® fib re collimator is comprised of a 0.25 pi tch GRIN lens and a 200~lm 
fi bre with nwnerical aperture of 0.50 and beam divergence angle of 6.5°. The same 
fibre collimator is used for collecting the light passing through the cloud. An Ocean 
Optics fi bre optic variable attenuator FY A-UV controls the illuminating intensity. 
3.1.2. Measurement volume 
For an optical characteri sation there is always a question about the measured sample. 
The incident light may interact with an entire cloud or only wi th a limited part of the 
cloud. The light leaving the aeroso l cloud could be collected as a whole or at 
strategic places . The geometry of the illuminating beam and co llecting optics defines 
the vo lume of the cloud that actually takes part in a given measurement. This vo lume 
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is often referred as the measurement vo lwne or the measurement sample. The choice 
of the ri ght sample is essential fo r the success of any optical technology. 
For this pilot investigation the collimated light illuminates a cylindrica l vo lume of 
1.9 millimetres diameter (d) and 25mm length (the diameter of the glass tube L). 
Figure 3.2 illustrates how the measurement vo lume depends also on the cloud 
velocity V el and the integration period"( of the detector; and Equation [3. 1] expresses 
thi s dependence in mathemati cal form : 
V -(v d JUI') L j"lIIlIplc - cl ti + 4 
L 
Vel' 
, 
\ 
I 
(3.11 
Figure 3.2. Schematic presentation of the measurement sample. A 
collimated beam of light illuminates a cylindrical volume at any single 
moment. During the measurement time, "t , the measurement sample 
increases accordingly to this scheme. 
This measurement volume could be considered as a representati ve sample of the 
cloud and at the same time it allows the dynamics of the aerosol development to be 
followed. The optimisation of the vo lume size requires future research and a further, 
narrower specifi cation fo r the system. 
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3.1.3. Sensor position 
The pos ition of the sensor down the stream of propagation produces a profound 
influence on the aerosol sample that has been actually measured. For example, if the 
sensor were adj acent to the mouthpiece of the inhaler, the measurement would 
characterise particl es in the immediate vicinity of the inhaler. In the case of p-MDl 
these would be fast-moving droplets of relati vely large sizes. The sensor placed, for 
example, 20cm down the stream would measure droplets of the smaller sizes due to 
evaporation and these droplets are moving slower due to relaxa tion to the velocity of 
the flow. 
The sensor records an accumulative effect of temporal and spatial vari ations in the 
cloud (see Chapter 2). The ri ght position fo r the sensor depends on the aims and 
purposes of the measurement. For example, mUltiple sensors placed along the cloud 
path may provide information on the cloud development. For pulmonary delivery the 
aim is to characteri se the cloud that is entering the respiratory system. In thi s case, 
the cloud in the middle of the mouth represents a viable sample of the particles, 
which would be avai lable for deep lung deposi ti on. In the prototype device fo r 
VariDose technology a di stance of 55111m from the inhaler mouthpiece has been 
used. This arrangement allows analys is of the drug cloud, which would be developed 
approximately in the middle of the patient ' s mouth and introduces only a small 
(- 30ml) extra vo lume for a patient to inhale. 
Particles moving along the glass tube are experiencing grav ity and interaction with 
the tube wall s. As a result, the walls are constantly contaminated with particle 
sediment. The wall sediment affects the intensities of the illuminating and co llected 
light. The res idue of fine particles can be taken into account by the data analysis and 
may even contribute to the aerosol's characterisation. On the contrary, large parti cles 
can considerably distort the measurement if one particle accidentall y fa ll s onto the 
optical window. To reduce the contamination of optical windows by large particles 
the attenuation measurement is performed in the horizontal plane. 
Figure 3.3 shows a set of the laboratory prototype device including: the sensor head, 
a light source, a breath-simulating machine and a spectrometer. As an example, on 
thi s picture VariDose is connected with a Turbohaler®, a reservo ir dry powder 
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inhaler. Out side the U.K. this inhaler is commonl y known as Turbuhaler. The 
auxi liary gas exchange cylinder prevents contamination of the breathing simulator 
with drug particles. 
Figure 3.3. Prototype device for VariDose technology. 
3.2. Data Acquisition. 
According to the model of VariDose technology, the data to be acquired are values 
of light intensity as a function of time. A light detector provides a signal that is 
proportional to the number of photons accumulated by the detector during the 
measurement period. The measurement period is a time period and is often referred 
to as the integration time for the detection system. The detector' s readings are 
streamed to computer memory with the time stamps, using an appropriate integration 
time. A computer stores the data for further analysis. The light illtensity, detector' s 
sensitivity and the integration time are the main variable parameters, which control 
the accuracy and efficiency of the measurement. At this stage of the technology 
development, the major objective was to prove the concept rather than to optimise 
the measurement parameters. Therefore, a readily available acquisi tion system with 
approximately suitable parameters has been used. The acquisition system consists of 
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an Ocean Optics spectrometer S2000 and AID converter ADC2000-PCI. The use of 
a spectrometer also permits an experimental evaluation ofthe spectral sensitivity. 
3.2.1. Acquisition frequency. 
The measurement object normally dictates the technical requirements for the 
acquisition system. The object for VariDose technology is an aerosol of particles. 
The aerosol is released by a delivery device and therefore possesses such 
characteri stics as vo lume, the start and the end of the cloud release, partic le 
properties and the propagation velocity. The cloud volume and geometric 
dimensions of the passage define the cloud length, which can be expressed in units 
of time or length. A single optical sensor records the light intensity as a function of 
time; therefore each ach13tion is characteri sed by a temporal profi le of light 
intensity. The question is how many measurement points are needed to be suffic ient 
for an adequate characterisation of the cloud? 
A typical requirement for airflow in the pulmonary drug delivery is 60L/min. An 
average person can inhale an air volume of 2.5L. This means that the inhalation 
duration is in the range of a few seconds. For successful delivery, the drug cloud has 
to occupy only the fro nt part of the inhaled volume. Only then can the drug particles 
reach the end of the conducting zone of the lung in one second, allowing particles to 
penetrate to the deep lung during the remaining period of inhalation. In the 25mm 
diameter tube the fl ow rate of 60L/min corresponds to an air velocity of 3m/sec. The 
duration of tJJe cloud (the temporal length of the cloud) may be well under one 
second. Ocean Optics supplies read ily available systems with the acquisition rate of 
200Hz. This frequency seems a suitable start for development of the proposed 
technology. The minimal integration time is 5 milliseconds allowing 20 data-points 
for a profile of 100 milli seconds. 
3.2.2. Attenuation value. 
Each set of experimental data is a two-dimensional array of light intensity in the 
time-spectral fi eld . The scattered losses of the co ll imated light are measured as an 
obscuration: a percentage of the light-intensity, which has been lost due to the 
scattering Obs(:i, / ) = 100 · [I -I(A,O/ lo(:i) ], where l(:i) and l a(:i) are intensities 
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of transmitted and illuminating light, respectively. The illuminating intensity may 
slightly fluctuate due to variations of the ambient conditions and would be reduced 
by the particle deposition on the walls of the air-passage. Therefore, the transmitted 
intensity through the sensor tube without the cloud is regarded as the incident 
intensity fo(A) = (I (A ,lo, !'J.l)) , where 10 , !'J.I is the time and the averag ing peri od, 
respectively. To address the issue of measuring the transmitted light just before the 
cloud entering the measurement volume, a special triggering procedure is employed. 
3.2.2.a. A spectral variation of the light obscuration. 
We have di scussed in Chapter 2 that the particle-light interaction depends on particle 
properties, both material and geometrical, and also on the light wavelength . We may 
expect that a spectral vari ation of the optica l obscuration will be caused by 
properties of the drug formulatio n. In this thesis, spectral variations of the 
obscuration have been studied on a few standard drug formu lati ons in the spectral 
range of 350nl11 to 85011111. This range is chosen to avo id the li ght absorption by 
electrons and phonons. In future research thi s material absorption can be used for 
gaining additional information about the drug in the cloud . For example, the drug 
might be marked with a strong optical absorption/emission li ne, and then the 
obscuration at thi s particular wavelength would be proportional to the drug amount. 
The obscuration at the given light wavelength Ai is obtained from the recorded two-
dimensional array of light intensity in the time-spectral field using the following 
formu la: 
[3.21 
where !'J.A is the spectral range for a few adjacent pixels of the speclrometer and the 
brackets ( .. .) denote averaging. 
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3.2.3. Triggering issues. 
The acquisition triggering is arranged in such a way that there are a few detector 
readings before the particle cloud reaches the observation plane. The mean value of 
these readings is taken as the illuminating intensity for the entire measurement of a 
cloud actuation. In thi s way, each measurement has the actual intensity of the light 
illumination. 
In most cases measurements can be triggered when the flow rate of the inhalation 
has reached a particular level. In cases, when airflow is created by a vacuum pump 
or when a p-MDI inhaler is not breath-actuated, the synchronisation of the actuation 
and the acquisition is difficult and a manual triggering is preferable. The manual 
triggering requires more computer memory per cloud-actuation and some skills from 
an operator. 
3.2.3.a. Software control. 
A virtual instrument developed uSll1g the LabView software controls the data 
acquisition. A standard code supp lied by the spectrometer manufac lllrer was used in 
subrouti nes fo r the software control of the acquisition process. 
3.3. Data Analysis. 
The model of the VariDose technology shows the relationship between the aeroso l 
content and the light obscuration at a given wavelength. The current technical 
so lution for the technology provides a spectrum of the transmitted light intensity for 
every 5 milli seconds. This two-dimensional array of data allows the extraction of an 
obscuration profile as a function of time for a given spectral range. Figure 3.4 
presents a few examples of obscuration profi les for a drug cloud released by an 
inhaler at the narrow spectra l range of 648ruu to 66611111. In general, profi les can be 
quite different due to the complexity of the cloud formation. 
How do we compare and assess them? Ideall y we are looking for a single va lue 
deduced frol11 the obscuration curve. A desirable feature of thi s value is a monotolli c 
dependence on the success of the drug delivery. 
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The shape of the profile is similar to the shape of emission/absorption lines in 
spectroscopy. Analogous to spectroscopy, the profi le can be characterised by the 
position of the maximum (the peak posi tion), the maximal value (the peak value) and 
the full width of the half maximum (FWHM). An analytical procedure has been 
deve loped to smooth the experimental data and to define basic characteristics for the 
measured profiles. 
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Figure 3.4. Examples of the light-obscuration profile for an aerosol cloud 
released by an inhaler. These profiles present different actuations of 
Bricanyl® Turbihaler® at the flow rate of 60Llmin. 
The possib le physical meanings of these parameters are introduced and discussed in 
thi s section. Here we also consider and decide on the optimal spectral range for the 
assessment of the fine particle dose in the case ofa dry-powder inhaler. 
3.3.1. Mathematical fit to an obscuration profile. 
The analysis procedure starts with fitting a smooth mathematical curve to the 
experimental data. The best fit has been achi eved by a sum of two functions with 
seven fining parameters. Figure 3.5 shows an example of the fining result. 
A lognormal functi on describes the smooth variation of the obscuration due to the 
presence of suspended particles in the air (curve I): 
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( {In[(t -a)j~W J exp - 2&2 
13.3\ 
where y is the obscuration data, I is the time variable and A , a , ~ and 6 are the 
fitting parameters. The fitting parameters refl ect the position and the shape of the 
curve I and are described in Table 3. 1. 
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Figure 3.5. An example of mathematical fitting to experimental data. 
A smooth transition between two levels (curve 2) IS describes by the fo llowing 
formula: 
Y2 (t) = R~ - exp[- a(t - b)]} [3.41 
This function has three fi tting parameters, R , a and b , and presents the light losses 
due to the particle residue on the walls. The zero attenuation level corresponds to 
clean walls and non-zero levels result from the particle residue. Physical meanings 
fo r the fitting parameters of thi s function are li sted in Table 3. 1. 
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Table 3.1. Description of fitting parameters. 
Fitting Description 
parameter 
A Relates to the peak value and characterises the maximal obscuration 
by an aerosol cloud. 
a Reflects the peak position and mainly characterises the triggering 
process. 
C, Relates to the time and might characterise the cloud ve locity. 
c Reflects the shape of the curve and characterises the FWHM. 
R Characterises the obscuration level by the particle residue on the 
wall s. 
et Reflects the slope of the transition between two levels and might 
characterise the wall deposition rate. 
b Reflects the position of the slope and characterises only the 
triggering process. 
Calculating the root mean square (nns) between the fitting functio n y = y, + Y2 and 
the experimental data, a computer program performs the iteration process to find the 
best fit. Final fitting parameters and the value of rms are used for characterisation of 
the aerosol cloud. The fitting parameters a, b reflect only the synchronisation 
between the cloud actuation and the start of data acquisition, and therefore do not 
contribute to the aerosol characterisation. 
3.3.2. Aerosol characterisation. 
The shape of an obscuration profile suggests poss ible parameters, which call be 
deduced and used for the aerosol characterisation. The most obvious parameter is the 
degree of deviation from the fitted curve. The root mean square estimates these 
deviations and may characterise the cloud homogeneity. The other interesting 
parameter is the maximum of obscuration, wllich according to the model (Chapter 2) 
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may be an indicator for the fine particle dose. There is a small obscuration that 
remai ns at the end of the profil e when the entire cloud has passed the sensor module. 
This remaining obscurat ion results from particles deposited on the wall s and may 
characteri se drug losses during propagation. Time-related parameters might measure 
the length and the asymmetry of the cloud. 
3.3.2.a. Cloud homogeneity. 
Inhomogeneous distribution of particles over the cloud causes fluctuations of the 
recorded obscuration. The large chunk of agglomerated particles strongly obscures 
the light beam, while a lack of fine particles results in a high transparency and a low 
obscuration. Fluxes of air turbulence create areas of higher and lower densities of the 
fine parti cles . This inhomogeneity results also in the obscuration fluctuations. The 
homogeneity (i-I) of the aerosol cloud has been estimated by calculating the 
fo llowing value fo r the fi tting results (y) and the measured data (Dal ): 
~((Y-Dal )2) l 
(Dal) 
I N (Dol)= - "L DOI , 
N '=1 
[3.5] 
[3.61 
The mean value for the data set ((Dell ) is calculated for the data points where the 
obscuration exceeds half of the maximal obscuration. In thi s way, if the data 
coincide with the fitted function the homogeneity equals 100%. This means the 
particles of all sizes are smoothly distributed over the cloud and there are no large 
chunks of agglomerates. Deviations from the fitted function result fro m lower 
homogeneity. 
3.3.2.b. Fine particle dose. 
The most important parameter fo r pulmonary drug deli very is the amount of fine 
parti cles, which actuall y reach the deep lung during a particular actuation. As we 
have discussed, the issue of the fine particle dose is a very complex matter with 
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respect to the aeroso l formation (refer to section 1.3 .). There are many components 
which affect the entrainment and development of an aerosol: 1) the deli very device 
itself; 2), the drug formul ation; 3) ambient conditions such as temperature and 
humidity; 4) the pati ent' s respirato ry effort and the profile of the fl ow rate. 
The li ght obscuration is also a result of complex interactions. Light interacts with a 
paJ"licle ensemble. If the num ber of particles in the ensemble, their geometrical and 
optical properti es , are known the li ght obscuration is stri ctl y defined and can be 
readily calculated. Unfortunately, there ex ists an aJl1biguity between the total pa rticle 
mass (vo lume concentration) and particle sizes . For example, a small amount of 
particles of I pm diameter produces much higher obscuration than the same mass of 
the larger particles . And the SaJlle level of obscuration can be produced by a small 
mass offine parti cles and by a much larger mass of coarse patiicl es (see Chapte r 2). 
Despite thi s complex ity, the peak value of the fitted curve I can be representative of 
the de-agglomeration level of the drug fo rm ulation if all mechanica l and optical 
conditions are the same. This means that for a given inhaler, with a fixed dose of a 
particul ar drug formulation and at a fi xed flow profil e, the peak value of the light 
obscuration can characteri se the degree of particle agglomeration. 
The peak value of curve I is a major featu re of the obscuration profi le. It may 
characterise the fine particl e dose in the aerosol cloud, which is the major parameter 
fo r the success of the pulmonary deli very . The ma in aim of thi s thesis is to seek the 
empiri cal support fo r this relati on between the peak value of obscuration and the fine 
particle dose. Note that the peak value of curve I takes into account on ly the 
p3.liicles in the air, whil e the wall' s res idue contributes to curve 2. 
3.3.2.c. Wall residue. 
Particl es deposited on the tube walls reduce the light intensities of the incident and 
tm nsmitted be3.l11 . The remaining obscuration, recorded by the sensor after the c loud 
has passed, is a characteristic measure of thi s particle sediment on the wall s. The 
rati o of the mean obscuration, caused by the sediment and the suspended particles, 
presents a units-independent value and can be expressed as a percentage: 
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A = I 00% -,,---"'-"-'----,,------N N 13.71 L>, (I,) + L>,(I, + Ll) 
i= 1 j: ] 
Averaging is performed over the same number of data for both fitted curves. For the 
curve I the data are for the time-moments when the obscuration is higher than half 
of the max imum. For the curve 2 the data are for the same time-period at the end of 
the recorded profil e. The time delay, Ll , refl ects the fact that the data fo r the 
sediment evaluation are taken later than the data for the cloud evaluati on, i.e. when 
the entire cloud of suspended pruticles left the sampling area. The value of thi s time 
delay depends on the cloud length and can be set as a multiple of the full width of 
the half maximum (FWHM). This ratio provides a characteri stic number fo r 
comparing dose-actuations within the same experimental set-up. 
The meaning of thi s parameter for the pulmonary deli very reflects the drug losses 
due to waLl deposition at a given moment of the cloud propagation, which is defined 
by the sensor position. It should be noted that, although the number is expressed as a 
percentage, it possesses no metrologica l meaning: it does not mean that thi s 
percentage of particles has been deposited on the walls. The wall-res idue parameter 
can be used only as a characteri sti c number for purposes of comparing diffe rent 
actuations in regards to drug losses due to the wall impaction . 
3.3.2.£1. Time related parameters. 
There are a number of time-related parameters, which can be deduced from the 
obscuration profile. A few of them deal with the length of the profil e. The full width 
at the half maximum (FWJ-lM) is a common pru'ameter for the characteri sation of 
bell shaped curves . The FWHM time ( LlI = / FWIIM _ t FWNM ) allows the PM/M "' "2 
calculation of the volume (M) of the cloud that contains the highest number of fine 
parti cles: 
(;unIt 
M = . JF(I)dl [3.8\ 
ftWfI.If 
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where F(/) is the flow rate of inhalation. 
The time width of the profile can also be measured at the lower leve l of obscuration 
than the half maximum. In this case the fitted curve I provides the fu ll length 
(!!./, = f xl -/ XI ) ofthe cloud for a given level (%) of the obscuration: 
[3.91 
where A , a, { and Ei are fi nal parameters of the best fi t. 
The curve I can be highly asymmetrica l. Mathematica ll y it is easy to introduce an 
asymmetry parameter, using the coord inate of the maximum and the level 
interceptions: 
'max- 'x1 Asym me / ry = --=-'-----"-'-
112- t ma.~ 
[3.101 
In some cases the asymmetry parameter may suggest the location of the fine 
particles in the cloud: in the front, in the centre or in the tai I of the released aerosol. 
One should be very cautious in making thi s type of conclusion due to the ambiguity 
of the light obscuration. 
Of special interest is the area under the fitted curve 1, which can be found by 
calculating the integral between two given points: 
'" _ If' ()d _ A 1[ In((t - a)/ ~ )][' 
'-' - Yl t t - er r;; 
[ 2 ev2 [ 
I I 
[3.11] 
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The phys ical meaning of the area is speculative and requires further investi gations. 
Table 3.2 summarises the characterisation parameters and their phys ical meaJ1\ng, 
based on generally accepted knowledge. 
Table 3.2. Parameters for aerosol characterisation . 
Parameter Description and physical meaning 
The measure of the hi ghest density of fine particles in a c loud. 
Defined as the maximum of the mathematically fitted function 
Peak value (eqn. [3 .3]). The measurement unit is the percent of obscuration; it 
is poss ible to calibrate as the mass of fine particles for a particula r 
inhaler-drug formulation combination . 
The measure of the cloud inhomogeneity such as large chunks and 
Wleven cloud density. DefUled as deviation from the exact fit using 
Homogeneity the root mean square eqn. [3.5]. The measurement unit is percent: 
100% means complete homogenei ty and the lower percentage 
means a higher inhomogeneity. 
The measure of the tube contamination by formu lati on particles 
after the passage o f the cloud. Defined as the rat io of the average 
Residue obscuration by the cloud and the remaining obscuration (eqn.[3.7]). 
The measurement unit is percent. The hjgher the val ue, the larger 
the deposit on the wall s and the higher the losses of the dose. 
The measure of the cloud vo lume. Defined as the time of the cloud 
Length propagation through the observation plane. The measurement unjt is the millisecond. The vo lume is calculated by integrating the fl ow 
rate profi le (eqn.[3.8]). 
The measure of the pos ition of fine particles (FP) in the c loud. 
Asymmetry Defined as the ratio of the front half and the ta il half of the cloud length (eqn. [3.10]). Value 1 means that the FP are in the middle; 
<1 in the fTont and > I in the tailing part. 
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3.4. Spectral sensitivity. 
We have developed the analysing routine that deri ves the quantified values from the 
shape of the obscuration profile and produces the indicator for the effectiveness of 
the pulmonary drug delivery. In the current experimental set-up the analys is can be 
performed at any light wavelength from the spectral range of the illuminating beam. 
An empirical investigation of which spectral range provides the better analys is was 
undertaken using the experimental data from Chapter 4. Two dry powder inhalers 
have been investi gated, the AstraZeneca Turbohaler® and a novel prototype device. 
The Turbohaler® is characterised by a relatively high fine particle fraction (of 
around 70%) and a high variation of emitted doses (the coeffi cient of variation is 
around 25%). The novel inhaler is characterised by an extremely high fine particle 
fraction (over 80%) and a low coefficient of variation. 
These two cases covered a signifi cant range of the pu lmonary deli very app li cations 
and may establ ish the range of light wavelengths, which is the most suitable for the 
assessment of the pulmonary-delivery effectiveness tlu-ough the VariDose 
technology. 
3.4.1. Spectrum of the illuminating beam. 
The spectrum of the light intensity, recorded by a detector, is usually a combined 
characteri stic of the light source, the detector's spectral sensitivity and the optica l 
properties of the optical path. In the current set-up the spectral output of the light 
source is between 350nm and 950mll with the power increasing from the lower 
wavelength to the higher one. For the detector the best efficiency (>30%) is in the 
range from 350Ill11 to 850Ill11 and peaks at 650mTI. Figure 3.6 presents spectra of the 
light, transmitted t1u-ough the VariDose system and recorded by the spectrometer, for 
a clean system (without a cloud) and for the system during and after an aerosol 
cloud. 
One can see that the entire spectral range of the current set-up is sensitive to the 
presence of the aerosol cloud . It is possible that different spectra l ranges may have 
di fferent sensitivities to the fine particles. The next section investigates the temporal 
profiles of the li ght obscuration against the light wavelength. 
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Figure 3.6. Spectrum of the illuminating light 
3.4.2. Spectral behaviou r of obscuration profiles. 
In the case of the Turbohaler® the released dose varies significantly in rela tion to 
both the metered dose (MD ) and the fine pal1icie fraction (FP F) . To fi nd out if the 
amount of fi ne particles affects tbe spectrum of the transmitted light we considered 
two actuati ons. One actuati on is characterised with the b.ighest FPF (76%) and 
another actuati on exhibits the lowest FPF (26%) for the data set presented in section 
4 .2. Temporal obscuration profiles are calculated for a nwnber of light wavelengths 
by averaging the intensities of a few spectrometer pixels in the wave length range. 
F igure 3.7 presents 3D-plots of the obscuration profil es against the light wavelength. 
The obscuration profil es follow a similar pattern for the entire spectral range and 
both actuations_ At the lower wavelengths (from 400run to 500nll1) and at the highest 
(850nm) the signal-to-noise ratio is not so good as fo r the middle values (from 
550nm to 800nm)_ There is less obscuration and more fluctuations fo r the dose ofthe 
smaller FPF tban for tbe dose of the larger FPF_ One can also see, tha t each 
indiv idual fluctuation exhibits itself in all profi les. The fluctuation o f the obscuration 
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relates to a temporal fraction of the cloud and characterises the particle population in 
this cloud fracti on regard less of the light wavelength. 
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Figure 3.7. Temporal profiles of the light obscuration at different wavelengths for 
an aerosol cloud, released by the Turbohaler®: a) the actuation , which is 
characterised with the high FPF=76%; b) the actuation, which is characterised 
with the low FPF=26%. 
Therefore, for the Turbohaler® applications any light wavelength within the range of 
SOOnm to 800nm may be used for the drug delivery assessment. 
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For another inhaler, a novel prototype, two actuations are characterised with the fine 
parti cle fraction of 90% and 94%, respective ly. Figure 3.8 shows 3D-plots of the 
light obscuration for these two clouds. The obscuration profi les are much smoother 
that in the Turbohaler® case, although the spectral behaviour is very similar. 
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Figure 3,g, Temporal profiles of the light obscuration at different wavelengths 
for an aerosol cloud, released by a novel prototype inhaler. 
For all four actuations, it seems that the li ght obscuration is smaller at the ' blue' end 
of the spectrum (up to 500nm) than at the higher wavelengths (from 550lUn to 
800nm). According to our model (please see Chapter 2), the peak obscuration may 
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be indicative of the fine particle dose of the actuation. Therefore, the large range of 
the parameter would benefit the accuracy of the dose measurement. Figure 3.9 
presents the peak obscuration as a function of the light wavelength for the four 
considered actuations. 
F rom the theoreti cal model (Chapter 2), we expect that the fine particles (the size 
range from O.S ~tm to Sf.lm) scattered the blue light (450nm) more than the other 
visible light (6S0nrn to 800nrn) (please see Figure 2.2). This contradiction between 
the experimental data and the model could be explained by the insufficient 
sensitivity of the experimental system to the blue light. Indeed, Figure 3.6 shows a 
very low intensity for the wavelength range from 350nm to 47Snm. At such low 
level of the light intensity, any cbanges of the transmitted intensity cannot be 
detected due to tbe insufficient sensitivity of the detector. The most likely reason for 
the low intensity of the blue light is the damping effect of the fibre patch on the rays 
of thi s spectral range. Therefore, to sinnultaneously investigate the obscuration effect 
for the blue, red and infrared light, the arrangement for the optical sensor should not 
include a fibre patch. 
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Figure 3.9. Spectral behaviour of the characteristic parameter, the peak 
obscuration, for four different dose actuations. The fine particle fraction is 26%, 
76%, 90% and 94%, respectively. 
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We can see that any wavelength within the range 500mn to 800nm would have a 
similar range of the peak obscuration for a wide range of fine particl e doses. For the 
sake of certainty (and practicality) the data analys is was performed only fo r the 
naJTOW range near 650mn. This wavelength corresponds to the highest sensitivity of 
the spectrometer and is likely to be less affected by both the thermal vibrations and 
electron exc itati ons of the drug formulation. The large range of the parameter wo uld 
also benefit the accuracy of the cl ose measurement. 
3.5. Summary. 
We have proposed and described in detail the in- line teclUlo logy fo r the assessment 
of the pulmonary drug delivery. This technology is named VariDose for its 
sensitivity to variations of the released dose on an actuation-by-actuation basis. The 
VariDose (VD) technology comprises the opt ical sensor, the data acqui si tion card 
and the software fo r data ana lys is. The stationary sensor records the spectrum of the 
transmitted light intensity as a temporal f"Unction. The spectral range near 6501Ull has 
been proven to be sensitive and to provide a sufficient range for the assessment of 
the fine paJticle dose. The analysis program calculates the tempora l profile of the 
light obscuration and fits these data with a mathematical f"Unction. The filt ing 
procedure requires six independent parameters. 
Several parameters are introduced aJld discussed for the aerosol characterisation 
using the best mathematical fit for the obscuration data. Table 3.2 presents the 
characteri sation parameters aJld their phys ical mean ing. The proposed physica l 
meaning of the deduced parameters is based on generall y accepted knowledge and 
needs to be validated with regard to the cloud propelt ies measured by conventional 
methods (CM). The main objectives are to establish empirica l relationships between 
the peak obscuration (VD) and the fi ne particle dose (CM). 
For thi s purposes a num ber of the speciall y designed experiments were performed, 
which are presented and discussed in Chapter 4. 
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A general concept for assessment of tbe pulmonary delivery in-line with a patient 
has been deve loped in Chapter 3. The model ca lculations (Chapter 2) show that 
VariDose data have the highest sensitivity to the fine particles and , therefore, it may 
be possible to measure the fine particle dose directly during the drug deli very. 
VariDose teclmology measures values that are proportional to the optica l density of 
the particle ensemble. Therefore, VariDose measures neither parti cle sizes nor 
parti cle-size distribution, but rather the degree to which the agglomerates of the drug 
formulation are di ssociated during an inhalation. In principle, fo r a given drug 
formulati on the VariDose data can be calibrated against the fine parti cle dose. This 
chapter presents a number of experiments, which support the teclmology concept. 
The aim of the first experiment is to show the technology's sensitivity to the fine 
particles. The second and third experiments present the calibration studies for several 
drug formulations perfo rmed with a Twin Stage Impinger (TSI) and a Next 
Generation Pharmaceutical Impactor (NGI). And the final experiment applies the 
VariDose method to the development of a novel delivery device and drug 
formulation. 
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4.1. Turbohaler® dose variation 
A TurbohaJer® is a dry powder inhaler wi th a multi-dose reservoir and a dose 
metering unit. This inhaler has been chosen for thi s experiment for two particular 
reasons. Firstly, it exhibits a significant variation of the delivered dose, even for a 
standard breathing manoeuvre . And secondly, it has significant clini cal usage and 
has been thoroughl y investi gated by many independent authors . In thi s experiment, 
for the teclmology eva luation we compare the VariDose data with the published 
result fo r single dose delivery efficiency of the Turbohaler® in Meakin et al., 
(1995). Meakin 's study was performed using a twin stage im pinger (TSJ). The aim 
of thi s comparison is to show that, even with no calibration, the VariDose method 
has the capability to assess the statistical variation of doses, released by an inhaler. 
4.1.1. Experimental set 
The Bricanyl® Turbohaler® device contains 100 actuations of pure terbutaline 
sulphate, housed in a small reservoir at the base of the inhaler. The metered dose is 
prepared by twisting the turning grip and by inhaling the drug particles through the 
spiral path mouthpiece of the Turbohaler. Each actuation is nom inated to conta in 
500 ~g of the medication. 
Inhaler ~JJQ/--;~5f:~- q Exhalation 
PC 
Auxil iary 
Gas 
Exchange 
Chamber 
"L----1----l AS L 5000 
Figure 4.1. Set up for the study of a dose variation of an inhaler by 
VariDose. 
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Figure 4.1 shows a schematic diagram and a photographic image of the experimental 
set-up. The Turbohaler is connected to the sensor unit of VariDose and a breathing 
simulator is actuating the dose release. The breathing simulator, Acti ve Servo Lung 
(ASL 5000), is manufactured by IngMar Medical and can simul ate the breath 
profi les based on the physiological model of the lung or reproduce the breath profile 
recorded from an actual pati ent; it can operate in a vacuum pump mode. To avoid the 
entry of the exhalation flow into the inhaler, a set of one-directional valves was used. 
The Aux iliary Gas Exchange Cylinder (AGEC) traps the particle cloud and prevents 
dust contami nation of ASL. 
The peak value of the obscuration is measured fo r each actuation at the li ght 
wave length of 650nm. According to the model (Chapter 2) thi s value characterises 
the max imum optical density of the cloud and can be considered to be proportional 
to the fi ne pal1icle dose fo r each individual actuatio n. After every ten actuations the 
glass tllbe of the sensor head was changed for a clean one. Stati stical ana lysis of the 
data was performed in terms of the mean value and vari ance . These a llow the spread 
and the frequency of the Turbohaler® dose vari ation to be shown. 
4_1.2. Inhalation profile. 
Severa l in vitro as well as in vivo stud ies have emphasised the importance of 
generating a particular inspiratory now profi le for dry powder inhalers (Clark et al., 
1996; de Boer et al., 1997; Bumell et al., 1996; Everard et al., 1996). The most 
important parameters are: 
• The peak inspirato ry fl ow rate (PIF); 
• The acceleration of the fl ow, the so-called now increase rate (FIR2o.so%); 
• The ti me needed to reach PIF (time to PIF); 
• The time during which a certain flow tlu·ough the inhaler can be maintained, 
the so-called dwell time; and 
• The total inspiratory volume. 
The breath-s imulating machine, used in our study, is multi-functional and can create 
a wide variety of inhalation profiles controlling many of the parameters mentioned 
above. For thi s comparative study the si mulated inhalati on manoeuvre is set in the 
way that most closely corresponds to the now required for the standard TSI protoco l 
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(British Pharmacopoeia, 1993). The breathing simulator works in the vacuum pump 
mode producing a steady inhalation flow of 60L/min with very sharp flow increase 
rate, the time to PJF is approximately 25msec. The total inhaled volume is set to 2.2 
litres. In this way it is possible to assume that the dose entrainment is similar to the 
TSI study and to make comparison between data, The inhalation cycle, which 
actuates the drug release, was followed by two further cycles at the higher 
inspiratory flow rate of 90Llmin. These additional inhalation cycles partially remove 
the wall residue, deposited dW'ing the inhaler actuated cycle. 
4.1.3. Results. 
For this study 60 available doses from two Turbohaler® devices from the same 
batch were used. The first 20 doses (shots I to 20) are fired from the first device and 
the other 40 doses (shots 21 to 60) are fired from the second device. All doses are the 
last doses of the device' s range, i. e. actuations 81 to 100 and 61 to 100, respectively. 
All 60 doses were separately analysed by VariDose and the peak obscuration is 
regarded as the dose value for the individual actuation. 1n this experiment we analyse 
the statistical variation of the VariDose data to answer the following questions: 
a) Is there any bias in sequential sets of VariDose measurements? Does the tube 
wall residue affect the measurements? 
b) Are VariDose data in agreement with a known statistical behaviour of the 
pulmonary delivery system? 
4.I.3.a. Issues of the wall residue. 
The paJ1ic1e deposit on the walls of the sensor glass tube may cause a bias ill the 
VariDose measurement. One might think that using a clean tube for each dose 
actuation would benefit the precision of measurements. In reality the process of 
particle deposition on the wall is complex and depends on many factors , often 
unknown and unpredictable, such as electrical charges of particles and absorption 
centres on the wall sW'face. In some cases "primed" walls, with small residues of a 
fine powder, cause less paJ,ticle deposition than the clean walls. Indeed, fine particles 
interact with absorption centres neutralising their absorption ability. Therefore for 
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the next dose actuation there are no trapping centres on the walls and less particle 
deposition. 
Figure 4.2 shows a variation of the dose value for 60 consecutive actuations of the 
Bricanyl® Turbohaler®. The absc issa gridlines indicate the moments of changing 
the glass tube, after every ten actuations. There is no noticeable repeated pattern in 
these sub-sequences. There is also no tendency of the dose vari ation over the entire 
sequence (no increas ing/decreas ing bias). 
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Figure 4.2. VariDose data of the dose variation for a Turbohaler®. 
To support these visual observations we performed a stati sti cal test, Analysis Of 
Variance (AN OVA) (Miller, 1997). This test can detect significant differences 
between several treatments. The requirements for this test are: 
I. The same number of replicates for each treatment (in our case there are 10 
actuations per each subsequence); 
2. All treatments (in our case six sub-sequences) have similar variance. 
To check if ollr treatments have similar variance, we use a statistica l test for the 
homogeneity of variance. We calclliate the variance for each treatment 
0' 2 = L(X -(X)~_ I) ' where (x) is the treatment's mean and n= 10 is the 
number of replicates per treatment. The test statis tic for homogeneity of variance is 
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the ratio of the highest value of the variance to its lowest value; and for our data (see 
Table 4. J) it equals 4.26. The hypothesis of homogeneity of variance is true, when 
the test statistic does not exceed the tabulated value of Fm"", which depends on the 
number of treatments and the degrees of freedom (n- I). In our case Fma, equals 7.80. 
Therefore, the null hypothesis of the homogeneity of variance is tTue and we are safe 
to proceed with the ANOVA test. 
There are six groups of measurements (u = 6, treatments A, ... ,F). Each group 
contains 10 measurements (v = J 0). Analysis of Variance involves the partitioning 
of the tota l variance into (I) variance associated with the different groups and (2) 
random variance, evidenced by the variability within the groups. The sample 
variance is defined as the sum of squares of deviations (SS) divided by the degree of 
freedom (cif = n -I, where n is the population number of the sample). According to 
the ANOVA algo ritlun we calcu late the fo llowing values, where the j-index relates 
to the actuation number within the gro up and the i-index presenls differenl groups: 
U I ' 
A= Ll>~; 
i=1 j= 1 
" B=L 
;= 1 v 
14.11 
Then, the SLIDl of tile squares of deviations between the groups is B - D and the 
degree of freedom is df = u - J . For the variance within groups SS = A - Band 
df = U( I/ - J). Finall y, for the total popUlation SS = A - D and cif = U 11- J . Table 
4. 1 presents the summary of the ANOV A test for the VariDose data. 
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Table 4.1. Summary of the analysis of variance (ANOVA test). 
Summary 
Groups Count Sum Average Variance 
Treatment A 10 53.95 5.395 1.677 
Treatment B 10 51 .23 5.123 2.700 
Treatment C 10 67 .70 6.770 2.289 
Treatment D 10 61.51 6.151 0.634 
Treatment E 10 60.66 6066 1.199 
Treatment F 10 59.56 5.956 2.692 
ANOVA 
Source of SS df MS F Variance 
Between 17094 5 3.419 1.833 Groups 
Within Groups 100.71 54 1.865 
Total 117.81 59 1.997 
Note for Table 4.1: SS is the sum of squares, df is the degree of freedom, MS is the 
mean of the sum of squares, and F is the statistic number. 
Using the mean squares in the final column of thi s table, we calculate a variance 
ratio test to obtain an F value: 
F=Between treatment mean square I Within groups mean square 14.21 
The calculated value F is compared with the F values from the test table for the 
different levels of significance (p value). If the calculated F value exceeds the 
tabulated value at p=0.05 there is significant difference between treatments. If so, it 
is necessary to see if the treatment differences are more highly sigtlificant by looking 
at the F values for p=O.OI and then 0.001. In our case the tabulated F value is equal 
to 2.4 for p=0.05, while the calculated F is only 1.833. Therefore, there are no 
significant di fferences between different groups of the VariDose measurements. 
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This test shows that for this drug formulation the wall residue during the sequence of 
ten actuations produces no noticeable effect on VariDose measurements. The overall 
set of data can be considered as the sample population for the identification of the 
distribution parameters such as mean, variance and standard deviation. 
In the next section we compare the distribution of the Turbohaler doses measured by 
VariDose and the published data on the Turbohaler dose vari ation measured by a 
conventional twin stage impinger (TSI) (Meakin et al. , 1995). 
4.1.3.h. Dose variation. 
In Meakin 's study eleven devices of the same batch (lot E in the reference, Meakin 
et al., 1995) were investigated to establi sh the degree of replication and evaluate the 
comparative performance of the Turbohaler®. Shots from I to 10 of each device 
were fired to waste and the following shots from 11 to 20 were evaluated. Ten doses 
of each device were measured by a twin-stage impinger to provide the emitted dose 
and the fine patticle dose for the individua l actuation (a total of 110 actuations). The 
coefficient of variation is reported as 17.3% for emitted doses (EO) and 25% for the 
fine particle doses (FPD), respectively . 
In the VariDose study the mean va lue of the peak obscuration is 5.9 1 % with the 
standard deviation of 1.41 3%. The coefficient of variation is 23.9%, which is very 
similar to the coefficient of variation of FPOs in the Meakin 's study. We would like 
to test if these two data sets belong to the same distribution. The Kolmogorov-
Smirnov test, KS-test (Kanj i, 1999), can determine if two samples differ 
significantly without making at1 assumption about the di stribution, and therefore, can 
establish differences in the distribution for these two datasets. 
For the KS-test the dataset is graphically presented through the cumulative fraction 
function, which can also be referred to as the empirical distribution function. To 
calculate the cumulative fraction function , the data is sorted in ascend ing order. 
Then, for each data-point, the fraction of the data smaller than this data-point is 
calculated. The cumulative fraction function is plotted against data-values. Both 
sample data are presented on the same graph, and the maximwn vertica l deviation 
between the two curves is the statistical value 0 of the KS-test. If the observed val ue 
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exceeds the critical value (from the test' s table), the null hypothesis that the two 
population di stributions are identical is rejected. 
To perform the KS-test for the VariDose data and the TS! measurements, the dose 
values have to be expressed in the same measurement uni ts . For thi s purpose we 
Dose presented the dose value as a percentage of the mean value, ( ) I 00% . 
mean Dose 
Figure 4.3 shows the cumulative fraction function of the dose value for single doses 
emitted from the Turbohaler®. 
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Figure 4.3. Cumulative fraction function for single doses emitted from 
the Turbohaler®. 
The maximal difference between two curves is 0.13 3. This value does not exceed the 
critical value even for the level of significance a = 0.20 ( D",,;co' = 0. 138, 0.157 and 
0.210 for a = 0.20, 0.1 and 0.01 , respecti vely). This means that there are no 
significant differences between these two di stributions and we can conclude with a 
high degree of celiainty that data of these two datasets are similarly distributed. 
This experiment shows that VariDose technology has realistically assessed the 
statis tical di stribution of the fine particle doses released by the Turbohaler®. During 
thi s experi ment we have accidentally found one of the benefits of the VariDose 
tec1mology, namely its ability to provide a quick assessment of the inhaler 
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perfo rmance In relation to the fi ne particle dose. The next section describes thi s 
episode. 
4.1.3.c. Quick check on an inhaler routine. 
The main benefit of the VariDose fo r anyone involved in the testing and develop ing 
of a pulmonary delivery system is as a quick and simple too l to estimate the emitted 
fine particle dose. An example of a quick check on one aspect of the inhaler 
performance is considered here. 
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Figure 4.4. Incorrect use of Turbohaler®. 
The leaflet for the Turbohaler® 
instructs the user to twist the 
grip keeping the inhaler in a 
vertical position when prepari ng 
the dose. This instruction is very 
easy to overlook. To find Ollt 
what happens if thi s req uirement 
is not fu lfilled, the Turbohaler® 
inhaler is connected to the 
sensor head of the V ari Dose in 
the horizoll tal position. The 
fifteen consecutive doses were prepared, actuated and evaluated. Figure 4.4 shows 
that emi tted doses of single actuation are signi ficantly decreased after a few incorrect 
preparations of the metered dose. 
The entire test took only 10 minutes. At the end of the test one can be absolutely 
certain that the chosen routine is incorrect, although the dose va lues are expressed 
onl y in arbi trary units. 
4.1.4. Conclusions. 
This straightforward and simple study shows that VariDose teclmology, in the case 
of the Turbohaler®, correctly reflects the statistical variation of the emitted doses. 
This supports the idea that the optical obscuration can provide a measure of the 
released dose without measuring the size distribution and weight of aeroso l parti cles. 
The main requirement fo r success is that only one parameter should be allowed to 
vary. In this experiment the inspiratory flow profi le, the drug fo rmulation and the 
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deli very device were constant. Therefore the change of optical obscurat ion can be 
attributed to the change of aeroso l content. 
4.2. Calibration of VariDose against TSI. 
The ai m of the second study is to investi gate the possibility of estab li shing the 
ca li brating relationship between the VariDose data and the data conventionally used 
for the evaluation of a pulmonary delivery system. The simplest conventional way is 
measurements by a twin-stage impinger (TS I). The TSl evaluates the fine particle 
dose and the coarse particle dose in terms of weight units . Therefore a s imultaneous 
analysis of the delivered dose by VariDose technology and a twin-stage impinger 
(TSJ) may calibrate the optical data of the VariDose into weight units. This study is 
al so perfo rmed on the Turbohaler®. This inhaler delivers relatively high doses of 
fine particles and exhibits a large dose variation, and therefore, one can ex pect a 
signi fi cant range of fine particle doses. 
4.2.1. Experimental set-up. 
A schematic diagram of the experimental set-up is presented in Figure 4.5. The 
sensor head of the VariDose (VD) is placed between the mouthpiece of the inhaler 
and the entrance of the TS I. As in the previous experiment, the sensor head of the 
VariDose has a vo lume of 30ml and optical measmements take place at a 50mm 
distance from the mouthpiece of the inhaler. The Bricanyl® Turbohaler®, 
contain ing 100 actuations of pure terbutal ine sulphate is used as the test inhaler. 
Each actuation is nominated to contain 500 ~lg ofterbutaline sulphate. 
The total dose, the fine particle dose and the fine particle fraction were determined 
using Apparatus A (British Pharmacopoeia, 1993), a glass twin-stage impinger 
(TSJ), calibrated at a flow rate of 60 ± 5 Llmin. The VariDose measurement was 
performed on the cloud, entering the inlet of the TSJ during Turbohaler firi ng. For 
each single Tmbohaler actuation the drug was collected and evaluated for three 
stages: the ' throat' , stage 1 and stage 2. The TSl was assembled with 7ml of solvent 
in stage I and 30 ml in stage 2. Drug samples, co llected on each stage of the TS I, 
were washed out with purified water. Each sample was fi ll ed up to 100 m!. The 
CHAPTER 4 92 
EXPERIMENTAL EVALUATION 
concentration of terbutaline sulphate was analysed by fluorescence spectroscopy, 
us ing an excitation wavelength of 273 !UTI and the emission wavelength of 311 IUTI. 
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Figure 4.5. A schematic diagram of the experimental set-up for 
simultaneous measurements by VariDose and TSI. 
Particles with mass median aerodynamic diameter (MMAD) 0.5-6.4 [-UTI are trapped 
in stage 2 and are considered as the fine particle dose (FPD), which is ab le to reach 
the lung. The total delivered dose is defined as the total amount of drug de li vered to 
the TSI under the experimental conditions, i.e. the sum of three stages. The fine 
pat1icle fraction (FPF) is the mass of drug deposited in stage 2· expressed as a 
percentage of the total dose. 
4.2.2. Results. 
A sequence of 21 actuations was performed, representing a typical variat ion in the 
total released dose and the fine particle dose for the Turbohaler®. Figure 4.6 shows 
the amount of terbuta li ne su lphate recovered in the twin stage impinger as the fine 
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particle dose and the delivered dose on actuation from the Turbohaler device at 
60L/min . The mean FPO was l72pg and the mean delivered dose 260)lg with the 
coefficients of variation 45% and 27%, respectively. The mean FPF was 63% with 
the coefficient of variation being 27%. 
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Figure 4.6. Deposition of Terbutaline Sulphate as Fine Particle Dose (Stage 
2) and Delivered Dose in the Twin-stage Impinger at 60llmin (n=21). 
4.2.2.a. Fine particle dose. 
The VariOose system can measure a number of parameters, wh ich assess the 
physical properties of the particle cloud (please refer to section 3.3). Figure 4.7 
presents obscuration profil es for two actuations, which are characterised by the TSl 
with the highest and the lowest fine particle doses. One can see that both profiles 
may be characteri sed with very similar cloud voltunes. For tllis experiment, when the 
flow is provided by a calibrated vacuum pump, the cloud vo lume is linearl y 
proportional to the propagation duration (the temporal length of the cloud). As we 
have discussed (Chapter 2), the obscuration depends on the vo lume concentration of 
the airborne material and the particle size distribution. The mean volume 
concentration is linearly proportional to the delivered dose due to the cloud having 
approximate ly the same vo lume fo r all actuations, but the spatial d istribution of 
palticles is unknown. 
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There is an ambiguity in optical obscuration: a high obscuration value can be 
explained by a high concentration of airborne matter as well as by a high fraction of 
the fine particles and at a much smaller concentration (section 2.3.2). The TSI data 
show that DD, FPO and FPF vary significantly for individual actuations. Here we 
consider a few estimations to chose a parameter of the obscuration profile, which 
would most reliably characteri se the fine particle dose in the released cloud when all 
three components (DD, FPD and FPF) have a wide range of variation. 
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Figure 4.7. Examples of the VariOose obscuration profile for drug 
actuations with the lowest and the highest FPO as measured by TSI. 
From Figure 4.7 we may estimate the minimal cloud volume that corresponds to the 
peak obscuration. There are 4 measurement periods on the top of the profi le. This 
gives the peak duration of 20msec; and at the flow rate of 60Llmin this results in the 
volume of 20mL. The highest DD, measured by TSl, is 361 ~g. Assume that this 
total mass of the drug formulation is concentrated inside the estimated vo lume of 
20mL and the material density is 1.54g/cm3, then the vo lume concentration (Cv) of 
the airborne material would be IOppm (parts per million). If all this matter would be 
spheres of 1 ~lln the light obscuration would reach 27% according to the model 
(please refer to Figure 2.3). While if the same amount of the matter would be spheres 
of 6 ~m the light obscuration would be onl y 4%. Therefore, the obscuration, caused 
by coarse particles (>6 ~m), is expected not to exceed 4%. In reality, particles may 
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be spread over the entire cloud volume (150mL, meaning the seven-times lower Cv) 
and parti cle sizes may be larger than 6 ~lIn (meaning the smaller ex tinction 
coefficients), therefore the maximal obscuration due to coarse particles might be 
significantly lower than 4%. 
The measured peak obscumtion ranges from 4% to 25% for different actuat ions. 
These are we ll inside the estimated va lues and just above the estimated max imum 
for the coarse particles. It is reasonable to suggest that the peak obscuration relales to 
the cloud part with the highest fraction of fine particles and may correlale wi th the 
fine particle dose of an actuation. The other possible parameter in this experiment, 
which may correlate with FPO, would be the area under the profile curve between 
two points, for example, at the half max imum of the obscuration (the so-called full 
width of the half maximum, FWI-IM). For convenience, we call thi s parameter ·' the 
dose value", reflecting the integral of obscuration. 
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Figure 4.8. A calibration of the VariDose parameter, the peak value, 
against the fine particle dose, measured by TSI. 
Ex perimental data show a stat istically significant correlation between the fine 
particle dose, measured by TSI, and the peak value of obscuration as defined by the 
VariOose teclUlology. The correlation coefficient is 0.94 and p<O.OOO I. In contrast 
the correlation coefficient of FPO against the dose value parameter is only 0.48 and 
p=0.03. Figure 4.8 presents a calibration plot for the fine particle dose in the released 
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aeroso l, measured by the two methods. The best-fit line goes through the origin and 
can serve to calibrate VariDose measurements in term of mass units. 
The noticeable spread of data (up to ± 25% from the fitted straight line) may be 
attributed to the fact that the VariDose sensor is placed up-stream to the TS1. [t is 
we ll known, that for dry powder formu lations the backside of the L-shaped throat 
may serve as an additional de-agglomeration stage through the bouncing mechanism 
(Dzubay et al., 1976). Covering the throat-stage surface with a 'sticky stuff can 
reduce th is effect (Turner et al., 1987; Dunbar el al. , 2005), but thi s is not a 
regu latory requirement and very often is not used because it increases labour and 
time burdens on measurements and reduces perfornlance-important values of FPD. 
This experi ment was conducted in collaboration with the Department of Pharmacy 
and Pharmaco logy of the University of Bath. Unfortunate ly, they were re luctant to 
use the 'sticky stuff in the throat piece of TSl to improve the accuracy of the 
ca libration. Currently, we can only conclude that the spread of the obse rved data 
does not entirely reflect the accuracy of the VariDose teclmology, but rather may 
illustrate some di sadvantages of the TSI measurement. 
The coefficient of variation for both methods is found to be s imilar: 45% for the TSI 
measurements and 48% for VariDose. The observed large variation is consistent 
with typica l dose variations delivered by the Turbohaler® device (Hind le el al., 
1995; Kamin el al., 2002; Meakin el al., 1995) rather than the vari ation of VariDose 
or TSl measurements. 
4.2.2.h. Cloud homogeneity. 
The homogeneity of the aerosol cloud, released by an inhaler, is not currentl y 
assessed by any technology commonl y used in the pharmaceutical industry. It is 
difficult to predict if thi s parameter is important for the efficiency of pulmonary drug 
delivery, but from the general physical point of view a more homogeneous cloud 
might benefit the lung deposition. In this thesis the data on c loud homogeneity are 
presented with the only purpose of gathering empirical data for future research. 
For this experiment we have used a readily availab le medication, which is widely 
prescribed by doctors, with the trade name Bricanyl® Tlll'bohaler®. This system of 
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the drug formulation and the delivery device has been rigorously tested, including 
clinical studies, and has passed the strict regulatory requirements. It is likely that thi s 
lengthy process of development and optimisation of the system explains the high 
homogenei ty of the released cloud. Figure 4.9 presents the homogeneity parameter 
of each actuation against the fine particle dose of this actuation . For comparison the 
homogeneity is plotted against two values of the fUle particle dose (FPO): one 
measured by the TS1 (diamante-markers) and the other assessed by VariDose using 
the calibration for the 'peak-va lue' parameter (asterisk-markers) . One can see that 
the actuatioLls of a higher FPD are characteri sed with a slightly better homogeneity 
than the actuations of a lower FPO. 
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Figure 4.9. Experimental data on the homogeneity of aerosol clouds 
released from a Turbohaler®. 
The homogeneity parameter may be useful during the development process of a 
pulmonary system. These include the development of delivery devices, drug 
formulations and a process of matching a drug formulation with a delivery device. 
For example, the VariDose assessment of the aerosol homogeneity can detect 
tec\U1ical so lutions, which result in the low homogeneity. In this way, a developer 
may quickly narrow options before going to in vitro measurements that are labour 
and time consuming. 
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4.2.3. Conclusions. 
Aerosol doses, released by a Turbohaler®, have been simultaneously assessed using 
two technologies: a twin stage impinger and the VariDose optical method. 
Experimental data show a good correlation for measured values of the fine particle 
doses. The correlation coefficient is 0.94 with the p-value of less than 0.0001. This 
experiment proved that the VariDose teclmology could be calibrated for mass units 
of the fine particle dose for a particular case. This means that for this chosen drug 
formu lation and the chosen delivery device the peak value of the obscuration profile 
characterises the fine particle dose in the released aeroso l and could be expressed in 
the mass units. 
Having thi s cali bration, it is no w possib le to assess without using an impactor many 
practical aspects: 
• Statistical vari ation of FPD for the entire content of the Turbohaler® device. 
The time saving could be enormous. The measurement rate for VariDose is a 
minute instead of hours for an inertial impactor. 
• Statistical variation between different inhaler devices and different batches 
can be measured in homs, not months. 
• The performance of the drug formulation can be quickly assessed during 
prolonged storage. 
• The suitabili ty of the Turbohaler® for a particular patient can be estab li shed. 
The breath-simulating machine actuates the dose release by applying the flow 
profile recorded for this patient and VariDose measures the FPD. 
• An individual patient can be monitored in respect of the actual dosage using 
the VariDose sensor attached to the Turbohaler®. 
The homogeneity parameter may be useful during the development process of a 
pulmonary system. These include the development of delivery devices, drug 
formu lations and a process of matching a drug formulation with a delivery device. 
For example, the VariDose assessment of the aerosol homogeneity can detect 
technical solutions, which result in the low homogeneity. In this way, a developer 
may quickly narrow options before going to in vitro measurements that are labour 
and time consuming. 
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4.3. Comparing in-Line optical and NGI measurements. 
The next step in the evaluation of this emerging technology is to use a different type 
of the drug formulation and another delivery device. It is also important to see how 
different species of the fine particles affect the li ght obscuration. Thi s experiment is 
design to test the applicability of the VariDose technology to a ca rri er-based 
formulation and a delivery device with high FPF. The purpose of the stud y is to 
compare the optical data of Varidose and the impaction data of a multi-stage 
impactor considering a number of size-classes in the range of the fine particles. 
4.3 .1. Experimenta l set-up. 
The experimenta l set-up includes a Next Generation Pharmaceutical [mpactor (NG I), 
Varidose and a Vectura prototype acti ve inhaler device. The dose actuation is 
faci litated by a vacu um pump at the flow rate of 60 Llmin. Figure 4. '10 shows a 
diagram of the experimental set-up . All connections between the devices are airti ght. 
The sensor-head of Varidose has an internal vo lume of approx imately 30mL (that is 
much smalle r than the NGI 's vo lume) and contributes a negligible air-resistance. 
to-
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Figure 4.10. A schematic diagram of the experimental set up shows the 
airtight connection of the pharmaceutical impactor NGI, the optical 
sensor-head of Varidose (VD) and the delivery device. The arrow 
represents the flow direction, created by a vacuum pump. 
The NGl system consists of nine impaction stages. Each stage co ll ects particles of 
the specified aerodynamic sizes and is characteri sed by the median of the diameter 
distribution (Dso). The median parameters for the NGI system range from O. JJ~(m to 
10f!m: I O~un (the Throat), 7.8f!111, 4.6f!m , 2.7 ~(m , 1.6f!m, 0.9f!m, 0.5~(m, O.3~(m anel 
0.13 f!m (the final Filter). The result of the NGI measurement is the distribution of 
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the drug mass over particle aerodynamic-sizes according to the drug mass co ll ected 
on each stage. The drug mass is measured by the photo-luminescence assay. The 
number of co llection stages and the sensitivity limit of the assay prohi bit a single 
shot NG I measurement, therefore a cumulati ve sequence of five actuations is 
analysed as a single assay-run . On the contrary, Varidose measures each single 
actuation. 
The prototype active inhaler device is a breath-actuated system and creates aerosols 
from a single-dose bli ster of a powder formulation. Doses delivered fro m thi s unit 
are usually characteri sed wi th a high Fine Particle Fraction (FPF). For thi s study we 
used a so-called carri er-based drug form ulation, which includes the micronised 
salbutamol sulphate (40%), the drug, and Respitose (60%), the carri er particles. 
Respitose is a lactose powder with the particle range of 45 ~lm to 90~lm . A signifi cant 
advantage of using this fo rmulation is the [act that Respitose particles of these s izes 
have negligible contri bution to optica l effects measured by Vari dose. Therefo re, 
neither NGI nor Varidose assesses Respitose particles. 
Measw'ements were performed using blisters with a formulation load of 
approximately 0.8mg and 1.0mg. Due to the hand fillin g of the bl isters there are 
sl ight variations in the metered dose (MD). Metered doses of the drug range from 
320~lg to 336f1g and from 400~lg to 424~lg fo r the two types of bl ister, respectively. 
The two different loads are intended to allow Varidose cali bration over a range o f 
powder doses . 
The sensor pos ition is kept the same fo r a ll experiments in thi s thesis, 5cm frol11 the 
mouthpiece of the inhaler. The temporal resolution is 5msec. This arrangement 
ensures that the opti cal measurement is made on the cloud, which would be 
developed in the middle of the pati ent 's mouth, and results in suffic ient data-points 
for analytica l purposes. 
4.3.2. Results. 
Overall , 30 actuations of the de livery device have been s imultaneously analysed by 
Varidose and the Next Generation Pharmaceutical lmpactor (NGl ). The NG I 
produced six sets of data averaged over fi ve consecut ive actuations, while Varidose 
C HAPTER 4 10 1 
EXPER.IMENTAL EVALUATION 
characterised each individual actuation. Experimental results show a significant de-
agglomeration of drug particles at the airflow of 60L/min. The NO! results are 
compared against the optical parameters, supposing that the particle de-
agglomeration takes place mainly before entering the NO!, and that the NO! 
structme makes an insignificant contribution to the de-agglomeration process. 
4.3.2.a. NG! data. 
The NO! data-set presents drug masses co llected on the impactor stages per single 
actuation and are considered as the drug distribution over the aerodynamic particle 
sizes for the "average" cloud entrained. Table 4.2 summarises the NO! data for the 
six sets. The table also includes the median diameter Dso ' which corresponds to each 
stage at the flow rate of 60L/min. 
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Figure 4.11. Released doses measured by NGI: MD is the mean va lue of 
the metered dose and error bars show the STDV of the loads for the run ; 
DD is the delivered dose; FPD is the fine particle dose and FPF is the fine 
particle fraction. 
Using the size di stribution of the particles the NO! software calculates 
pharmaceutically important parameters: the Delivered Dose (DD), the Fine Particle 
Dose (FP D) and the Fine Particle Fraction (FPF). The definitions ofthese paran1eters 
are discussed in the section 1.3.3a of tlus thesis. Figure 4.11 shows a summary of the 
dose distribution through the given data sets. All released doses are characteri sed 
with high values of the FPF, which range approximately from 94% to 97% and 
corresponds to the fine particle masses, FPD, ranging from 226,tg to 324J.lg. 
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Table 4.2. Summary ofNGI data. 
Throat Stage I Stage 2 Slage 3 Stage 4 Stage 5 Stage 6 Stage 7 Fi Ite r 
Djo 
>10 7.8 4.6 2.7 1.6 0.9 0.5 0.3 0.13 
[flnl] 
Set I 
0.72 1.64 8.16 51.82 120.58 77.84 17.44 5.36 18.16 
[flg] 
Set 2 
0.72 10.94 12.8 62.04 129.86 79.70 17.44 5.36 26.54 
[flg] 
Set 3 
1.64 0.72 5.36 49.96 112.22 72.26 15.58 3.50 17.24 
[~lg] 
Set4 
0.72 0.72 5.36 39.74 94.56 62.98 10.02 1.64 16.30 
[flg] 
Set 5 
0.72 1.64 9.08 47.18 100.14 68.54 14.66 4.44 19.10 
[pg] 
Set 6 
0.72 4.44 10.02 43.46 102.00 75.98 13.72 3.50 20.02 
[ ~lg] 
For the blisters of 0.8mg the coefficient of variation of the delivered doses is 8.6%, 
whi le the variation coefficient for the formu lation loads is under 2.3%. Similar 
discrepancies are observed for 1.0mg blisters: 6.3% for the delivered doses and 2.0% 
for the formulation loads (MD). Therefore, although NGI gives no data on the single 
dose variation (they are averaged over 5 doses), the variation coefficient of the 
released doses for the blisters of the same load will be considered as the variation 
coefficient of a single dose. This approximation is the lowest estimation of the 
variation and is used to compare the NGI data wi th the VariDose data. 
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4.3.2.b. VariDose data. 
VariDose characterises each individual actuation by recording the temporal profile 
of the light transmission through the propagating cloud. Figure 4.12 shows a few 
profi les recorded for thi s experiment. Curve I presents the cloud with a higher FPO 
and curve 2 corresponds to the actuation of a smaller FPO. For comparison there is 
also a typica l profi le for the actuation containing only the Respitose component, 
without the drug load. To draw the obscuration on the logaritlmlic scale a small bias 
of 0.08% was added to al l data points avo iding negative values due to the 
measurement noise. 
Figure 4.12. Samples of the obscuration profi les. 
From these graphs one can see that the carrier particles only slightly contri bute to the 
obscuration. Therefore the majority of the obscuration should be attributed to the 
drug particles. 
The drug particles released by an inhaler consists of a large parti cle population. 
These particles possess different shapes and sizes and create an aerosol cloud of a 
certain limi ted vo lume. The particle distribution over the aerosol cloud is generall y 
unknown and can be highl y inhomogeneous. The temporal profile of the cloud 
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obscuration gives a "snap shot" of the variation of the clo ud 's opti cal density in 
space without reso lving the entire complexity of the time-space cloud development. 
To eva luate the cloud homogeneity we introduced a characteristic parameter named 
"homogeneity" (please refer to the model section 3.3.2.a). The cloud homogeneity 
measures the deviation of the experimental points from the fitted curve and ranges 
fro m 98% to 99% for these 30 actuations. This high homogeneity a llows the 
suggestion that particles are smoothly distributed in the cloud and that the model 
assumptions are f11lfilled. Next we compare the model calculation and the observed 
values of the obscuration . 
4.3.2.c. Comparing the model with the observed obscuration. 
The NOI data provide the size distribution of particles in the aeroso l. This 
di stri buti on has a number of limitations such as: I) the aerosol c loud is unreal, but 
average for a given assay-run; 2) there IS no information about the spatia l 
distribution of particles; and 3) there is an uncertainty that de-agglomeration 
processes have completed before the cloud enters the tlu'oat stage of the NOl. 
Despite these limitations, the NO] gives a good estimate of the particle contents in 
the cloud. The ratio of the drug mass of an individual stage to the total drug mass of 
all stages gives the fraction of each type of particles. Whil e the precise spatial 
distribution of particles is unknown, fo r estimation purposes we assume the 
homogeneous di stributions of particles over a limited cloud volume. Then, partia l 
vo lume concentrations of each particle type and equations [2.6J, [2. 19J, and [2.20J 
all ow the calcu1ation of the optical obscuration for an individual cloud . The onl y 
undefined paran1eter left is the cloud volume. 
The cloud vo lume can be estimated by the duration of the cloud and the flow rate. 
The flow rate is constant and equal to 60Umin. The duration is extracted from the 
temporal profile of obscuration. For visualisation of the fo llowing discussion, figure 
4. 13 shows one of the obscuration profiles and the chosen time periods. Consider 
tlu·ee time periods: 
I. The lowest time is the measurement peri od of Sms. It is quite absurd to 
suggest that all particles are assembled in such a vo lume when there are at 
least 20 measurement po ints in the profi le. This small time is used to estimate 
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the highest possible obscuration. In this case we assumed that the particles 
fi"om stage 4, which have the highest extinction coefficient, occupy on ly thi s 
small vo lume and all other particles are distributed over the entire cloud. 
2. The other characteristic time is the time period between two points at the half 
maximum of the obscuration. These values are referred to in this thesis as 
(FWHM and V FWHM for the time and volume, respectively. This time 
corresponds to the main body of the cloud. 
3. One of the largest clouds corresponds to the time period measured between 
two points of the interception of the fitted curve and the level line of 
obscuration. The obscuration of I % gives the largest cloud without 
interfering with the level of the residue obscuration. 
30 , ' 
.) 
o 
§ 20 
.~ 
~ --- -------- J' FWHM 
'" .0 , 
o ' 10 
v 
.} <;\)'),x.- 1 % level 
~~~=====1~OO~====='=~~~~~~=··~··~-3··~· ~30~0~~' 
Time (ms) 
Figure 4.13. A graphical presentation of definitions for the cloud duration 
and the cloud volume. 
Figure 4 .14 presents the results of the model calculations using the above 
assumptions. As we expected, the absurd suggestion that all particles are assembled 
in a small volwne, corresponded to a single measurement of 5ms, results in nearl y 
absolute obscuration (>90%). Th is result is invalid, because the obscuration values 
exceed 50% and therefore the model assumption of single scattering is broken. For 
such a dense media the light transmittance must be consider through the diffusion 
theory (Cha.ndrasekhar, 1960; Ishimaru, 1978). The case of the 5ms c loud has been 
considered here only to conclude that particles have to be di stributed in a larger 
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volume than 5mL. From the other point of view, a suggestion that all types of 
particles are homogeneously distributed tlHough the entire cloud, measured at the 
1% obscuration level, results in a rather lower obscuration than that observed in the 
experiment. 
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Figure 4.14. A comparison of the model calculations and VariDose 
measurements for the peak obscuration of an aerosol cloud . 
The best agreement between the model and experimental data is observed fo r an 
assumption that all particles are homogeneously dish-ibuted over the cloud vo lume, 
which corresponds to the full time width of the profile at the half max imum of the 
obscuJation (FWHM). 
4. 3.2. d. Value of the FPD. 
In the comparative study ofTS! and VariDose we used the Turbohaler® device and 
a drug formulation that contained only micronised drug particles. For that case the 
variation coefficient of the flI1e particle dose was high, 48%, the mean value of the 
fine particle fraction was 63% with the variation coefficient of 27%, and the peak 
value of obscuration (the maximum of the fitted curve) had a stati stically significant 
correlation, 0.94, with the FPD (section 4.2.2). On the contrary, for thi s study the 
variation coefficient of the de livered dose is well w1der 10% (8.6% and 6.3% for 
different loads of blisters), and the FPF ranges only from 94% to 97% (section 
4.3.2.a). There is one more significant difference between these two studies. In the 
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first study the cOITelation was established for the single actuations, while in the 
second study the correlation can be established only between the mean va lues for the 
NGI assay-runs. 
According to the method of the VariOose data analysis (section 3.3.2b) two 
parameters can characterise the FPO in the cloud: the "peak va lue" and the "dose 
value". The dose value is the integral of the fi tted cmve between two points, and 
therefore, it depends on the choice of these points. Here we consider two dose va lues 
OVFWHM and OV 1%, where the fu·st is the sum of the data that are larger than the half 
maximum, and the second is the integral of the filted curve between the points of the 
interception of this curve and the line of 1 % obscuration. 
To compare the sets of data for fine particle doses, the correlation between the mean 
values for the ind ividual nms is establi shed. The correlation coefficients for the NGI 
data of FPO and the peak values is onl y 0.57 wi th p=0.23. In the case of OVFWHM 
and FPO data, the correlation coefficient is 0.82 and p=0.05. Stat istically significant 
con·elation has been observed for the mean values of OV 10/, and the NGI data fo r 
FPO with the correlation coeffici ent of 0.87 and the p-value of 0.02. This signifi cant 
correlation can be used to calibrate the VariOose parameter of the fine particle dose 
DV 1% for the conventional mass units. It also indicates that the fine particles are 
distributed over the entire cloud and make the major contribution to the light 
obscuration. Therefore, to account for all fine particles in the released dose, the 
integral of the entire profile should be taken. This si tuation wou ld probably be true 
for all combinations of a delivery device and the drug formulation when actuations 
are characterised with a very high Fine Particle Fraction. 
Figme 4.15 shows a possible calibration of Varidose measurements for the given 
experimental set-up. The best fit for the experimental data (the so lid line) , ca lculated 
using the least squares method, is not crossing the orig in. Note that mean values of 
Varidose data are also characterised with variance, which refl ects the variation of the 
dose for a single actuation in each run of 5shots. The variation coefficient ranges 
from ± 4% to ± 10% for individual runs. Unfortwlately, the NGl provides only 
average values for each run. A single shot variation for the NGI data is adopted from 
the variation across the blisters of the same load. According to the calibration, the 
dose variation is within the dose range measured by NGI (dotted lines). This fac t 
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confirms that VariDose measurements may reliably characterise the fine particle 
dose for a single actuation, although the calibration precision wou ld benefit frol11 
more experimental data. 
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Figur'c 4.1 5. Data correlation of fine particle doses measured by NGI and 
Va riDose. 
4.3.3. Conclusions. 
This experiment shows that the VariDose teclUlo logy has been successfu lly applied 
to one more combination of the delivery device and the drug formulation. In this 
case delivered doses are characterised with a low variation coefficient and a high 
fine particle fraction . The one Varidose parameter that is related to the fine particle 
dose by the model shows a good correlation (the correlation coefficient 0.87 and 
p=0.02) with the fine particle dose measured by a next generation pharmaceutical 
impactor (NGT). It also demonstrates good agreement between the model predictions 
and the observed values of light obscuration. 
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4.4. Summary 
The laboratory prototype VariDose system has enabled the investi gation of the 
validity of several key assumptions and theoret ica l results used to obtain a model for 
the light obscuration by airborne particles in Ihe pulmonary drug deli very. The 
temporal length of the obscuration profile gives a good estimation for the cloud 
vo lume. The obscuration max imum lndicates a possible maximum of the particle 
concentration in the fine particle distribution. Several pulmonary delivery systems 
have been studied and practical assessments of the fine particle dose have been 
achieved. 
Simlrltaneous measurements of the drug delivery by the VariDose technology and 
conventiona l in vitro methods allow the evaluation of the performance of this qu ick, 
robust and in situ method. The practical experiments show that VariDose has been 
successfully applied for a statisti ca l assessment of the Turbohaler® performance. 
Usefu l results have been achi eved even without a calibration of the VariDose optical 
units into the mass units. The VariDose system can be " trained" to measure the mass 
of tbe de li vered fine particles through the calibration against an inertial impaction 
system. The training process has been tested on two benchmark systems: a well 
studied Turbohaler® with a "drug only" formulation , and an advanced prototype 
device wi th a carrier-based formu lation. These studies indicate a wide potential for 
the VariDose usage in the pharmaceutical industry and in the clinical management of 
pulmonary drug deli very. 
The Varidose teclmology is a useful tool for a quick assessment of the quality of 
pulmonary delivery in-line wi th a user, a lthough it cam lot entirely substi tute for an 
inertial impaction system. The wide area of unique and complementary app lications 
for Varidose is related to the specifics of its operation: 
• VariDose is much quicker (1 minute instead of hours) than any inerti al 
impaction system due to its capability of in-line direct measurement during a 
real actuation. 
• VariDose assesses the fine particle dose of a single actuation and can be 
calibrated to the mass un it for a given drug formulation. 
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• VariDose can operate in-line with a patient, as well as with a virtual patient 
(a breath simulating machine) or an impactor. 
VariDose can characteri se many physical properties of the aerosol cloud, which 
currently are not considered in relation to pulmonary delivery, such as the cloud 
homogeneity, the volume of the cloud, and the spatial location of fine partic les in the 
cloud. Some possib le future experiments are di scussed in Chapter 5. 
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Chapter 5 
Conclusions and Discussion 
The primary aim of thi s thes is has been to investi gate the poss ibility o f assess ing the 
pulmonary drug delivery in-line with a patient. For thi s purpose an optical method 
based on the interaction of li ght with particles has been des igned and tested in 
benchmark applicati ons. A theoreti ca l model has been developed and justifi ed fo r 
the operational principles of the method. It has been shown that thi s teclmology is 
successful in measuring the fine particle dose of an aerosol re leased by an inha ler. It 
is further suggested that this method not onl y fac ilitates the dose assessmen t in-li ne 
with a patient, but also improves the characteri sati on of aeroso ls to levels that have 
hitherto been impossible. 
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5.1. Conclusions 
Pulmonary drug delivery is a fast-growing branch in the healing and symptom-
managing therapies. The main attraction of inha ling dTugs is a rapid onset of action 
and more efficient and targeted treatment of I ung di sorders, i.e. small er doses are 
required in compari son to the oral delivery causing fewer systemic side effects. The 
pulmonary deli very is a non-invasive alternati ve to injection and, therefore, is a very 
attractive route for del ivering innovative, protein-based drugs. The pu lmonary route 
offers the highest bioavailability of any non-in vasive route and faci li tates more rapid 
drug absorption in the bloodstream compared with subcutaneous injecti on. 
Inhalation drug systems are a particulaTly attractive treatment option for di seases 
such as diabetes and mUltiple sclerosis and fo r pain, seizures, card iovascular events, 
anaphylax is and other conditions requirillg freq uent inj ections for a rapid symptom 
relief. 
For the rea li sation of the benefi ts of pulmonary drug delivery there are three main 
requirements: 
I. The drug has to be formulated to efficientl y reach the a lveo li of the deep 
lung, where it can be rapidly absorbed into the bloodstream. 
2. The de li very dev ice has to faci litate the entrainment and di spers ion of the 
drug formulation into an aerosol w ith particle sizes in the range of 0.5 1-1 m to 
51-1m. 
3. The patient has to be compliant with procedure and produce a suffi cient 
inhalation effort. 
Due to thi s complexity of the pulmonary drug delivery the actual del ivered dose is 
unknown. Complex in-vitro and in-vivo tests and cl inical trial s are needed to ensure 
a consistent performance of the drug fonnulati on and the delivery dev ice, although 
patient compliance and the ambient conditions, such as humidi ty and temperature, 
can signifi cantl y reduce the consistency of the deli vered dose. There is an 
und isputed need for a rapid technology to measure the delivered dose on an 
actuaLi on-by-actuation basis and in-li.ne with a patient. 
Thi s thesis has developed and principall y eva luated one of emerging technologies 
for an in-line, real-time assessment of the efficiency of pu lmonary d rug deli very. 
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The development aim was to bring the advantages of optical sensors, such as their 
non-invasive nature and ease of use, to the problem of a rapid and in-line assessment 
of the pulmonary drug delivery. The developed technology, the VariDose, exploits 
the phenomenon of light scattering by small particles. The unique relationship 
between the scattering cross-section and the particle size allows the finding of 
experimental conditions in which the fine particles of the pu lmonary delivery cause 
the majority of the light obscuration in comparison to the other aeroso l components. 
The theoretical model calculates for the first time the optical density of a small cloud 
sample using the Lambert-Beer law and the Mie theory. The size of the sample is 
defined by the geometry of the sensor: the dian1eter of the light beam, the length of 
the light path in the cloud, the freq uency of the measurement and the velocity of the 
cloud propagation. It has been shown that the temporal profile of the light 
obscuration, measured perpendicular to the direction of the cloud propagation, is 
indicative of the particle distribut ion in the cloud. In any given case, taking into 
account additionally availab le information, such as a nominated mass of the drug 
formulation and the cloud length (measured by VariDose), it is possible to find a 
single-number indicator for the fine particle dose. 
To utilise the VariDose techno logy a novel prototype device has been built and a 
number of evaluating experiments have been performed. The experimenta l results 
show a strong correlatio n between the VariDose measurements and the conventiona l 
in-vitro data. The simultaneous measurements on a Bricanyl® Turbohaler® by 
VariDose and a Twin Cascade Impinger (TSI) have resulted in the correlation 
coefficient of 0.94 and p<O .OOOI for the assessments of the fine particl e doses. 
It is also has been shown that the VariDose system can operate as a stand-alone 
teclUlology for a statistical assessment of the inhaler performance, as an example, the 
test performed on the Bricanyl® Turbohaler® was compared with published data. 
The coefficient of variation was 23 .9% for the VariDose assessment of the delivered 
doses. This is in good agreement with the 25% repOIted by Meakin (Meakin et al. , 
1995) for the coefficient of variation of the fine particle doses . The Kolmogorov-
Smirnov test, KS-test (Kanji , 1999), has estab li shed with a high degree of certainty 
that the data of these two datasets (VariDose and Meakin 's study) are similarl y 
distributed. 
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This research has proved that a relat ively simple optical sensor is able to provide a 
scaled ind icator for how well the drug formulation is di spersed during pu lmonary 
deli very and therefore may rapidly measure the delivered dose in-line with a patient. 
This techno logy can also be used for rapid assessment of iterati ve steps in innovating 
drug formu lations and de livery devices. The main advantages are single actuati on 
and real-time measurements. VariDose requires oIlly a few seconds (up to one 
minute, taking into account the inhaler preparation time) to assess a single dose 
actuation, instead of the two hours requ ired for a measurement by a cascade 
impactor. Add itionally, the proposed technology offers a novel area of research, 
investigating how the aerosol cloud is changing along the propagation path. 
5.2. Suggestions for future research. 
The main purpose of the current investigation was to prove the principle of the 
VariDose techno logy, that a simple optical sensor can offer a rap id and an 
informative assessment of the efficiency of the pulmonary delivery. The future 
research could contribute to the fo llowi ng areas: I ) the device moderni sation to 
improve its robustness; 2) the optimisation of measurement parameters such as the 
light wavelength , the light intensity and the rate of the data acquis ition; and 3) case 
studies to develop routines for typica l applications of the technology. Further 
interesting deve lopments may arise through exploring the use of light sources of 
various wave lengths and l11ultiple sensors . 
5.2.1. Technology modernisation. 
The whi te light source, fibre optic patches and miniature spectrometer of the current 
set-up are insuffici entl y robust for more general use. To improve the robustness of 
the method, the future VariDose device could be designed and built using light 
emitting diodes (LEDs) and semiconductor detectors . The use of LEDs allows a high 
rate of data acquisition, the acquisition rate can easily be 10kHz, this means that the 
moving cloud can be sampled every 100llsec. For the current design this rate wou ld 
provide a sampling of 300llm along the cloud length at the fl ow rate of 60Llmin. 
This high rate offers not onl y a high spatial reso lution of the cloud, but also a hi gh 
dynamic resolution for the multi-sensor applications. 
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The main challenge of using LEDs relates to the problem of creating a uniformly 
illuminating collimated beam of a small diameter and a relatively high intensity. 
Based on the current design, the requirements fo r the light beam can be summari sed 
as follows. The total power of the illuminating light is 30~lW, the beam diameter is 
1.8mm and the beam di vergence angle (2E» is 3.5 degrees. Special care needs to be 
taken to ensure the homogeneous di stribution of the light intensity over the cross 
section of the beam. 
The wide range of available LEDs would allow the optimisation of the parameters of 
the illuminating beam, such as light power and wavelength. These also permi t the 
exploration of the benefits of multi-wavelengths and mult i-sensor measurements. 
5.2.2. Technology applications. 
The VariDose technology has been deve loped and intended for the assessment of the 
effi ciency of the pulmonary delivery. There are many different applica ti ons in 
pharmacopoeias, where VariDose can provide significant benefits. The further 
investigation could evaluate these benefits for different app lications through 
performing case studies. 
The most straightforward studies relate to simultaneous measurements with the 
conventional pharmacopoeia methods such as inert ial cascade impactors. Figure S. l 
shows, as an example, an experimental set-up for the simultaneous measurements 
using an Andersen impactor and two Va.l'iDose sensors. The VariDose sensor can be 
placed either (or both) between the inha ler's mouthpiece and the uni versa l induction 
port (F igure S. l , position A) and between the USP and the impactor entrance (Figure 
5.1 , position B). The main purpose of these studies would be to show that the 
VariDose data are strongly correlated with the impactor measurements for the entire 
variety of cases. The studies need also to prove that the VariDose sensor does not 
affect the impactor performance. As soon as thi s relation is established, VariDose 
can be used as a stand-alone technology and can lead to an effecti ve and efficient 
design cycling, manufacturing and testing of the drug formu lation and the delivery 
devices. 
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A 
B 
Figure 5.1. Experimental set-up for a simultaneous assessment of the inhaler 
performance by VariDose and Andersen impactor. 
The other area of the study can exploit the VariDose' s ability to operate in-line with 
a patient. Here, a breath-simulating machine can act as a robotic patient and 
VariDose would assess the performance of the drug delivery. The study can be 
designed to reproduce a clin ical trial , which, for example, has been published. A 
statistical ana lysis would test that the outcomes of the clinical trial and the robotic 
trial are similar. 
By varying the breathing parameters, a possible influence of the patient' s inhalation 
effort on the outcome of the clinica l trial can also be studied. The aim of these 
studies would be to show that the VariDose technology could serve as a rapid, 
inexpensive, pre-clinical test for the pulmonal'Y delivery system. To prove the 
validi ty of this robotic trial would be of enormous benefit for the paediatric 
appl ications, where patients can breathe only spontaneously and cannot be trained 
for a special inhalation pattern. 
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5.2.3. Technology exploration. 
The natural exploration of the VariDose technology is based on the use of multi-
sensors. Multi-sensors along the path of the aerosol propagation would non-
invasively assess a real-time cloud evolution. Currently , the aerosol evolution can be 
assessed using ultra fast imaglng (Oxford Lasers, 2004), as we have di scussed ill 
section IA.2.a. This type of imaging can onl y be performed on an open aerosol, i.e. 
an aerosol, which propagates in an open space and not tlu·ough a conduit. Therefore, 
ultra fas t imaging of the aerosol evoluti on does not include two major facto rs that 
affect this evolution: the conduit's wall s and the inhalation flow. On the contrary, the 
VariDose techno logy may allow the influence of the flow rate and the conduit 
diameter on the aerosol evolution to be studied. 
Eventll3lly, it would be possible to build a replica of the conducting zone of the 
human respiratory tract with strategically placed sensors. The rep li ca may inc lude 
onl y the oropharYI1X, larynx, trachea and segmental bronchus. The multi -sensors 
would allow the evolution of the cloud during the propagation towards the lung' s 
respiratory zone to be investigated. 
The other area of fu rther research is more challenging and relates to the spectral 
behav iour of the light obscuration. It is well known, that fo r a single spherical 
particle the light extinction depends on the particle size and the light wavelength. For 
an aerosol cloud, an ensemble of particulates causes the light obscuratiol1 . The level 
of the obscured intensity depends on the anlount of ai rborne matter and the partic le 
size distribution in the cloud. The theoretical model, developed in this thesis, al lows 
for the calculation of the light transmittance through a well-defined cloud, i.e. the 
particle anl0unt and the particle di stribution are known. There is a strong indication 
that if the majority of particles are in the range of 0.2pm to 0.8pm the blue light 
(450nm) is scattered more than the red light (65011Jl1) and infra-red (800rull) (please 
refer to the section 2A.I). The challenge is to fll1d an experimental set-up for multi-
wavelength (multi-colour) measurements, which would permit measuring the co lour 
change between the transmitted light and the illuminating light. The aim is to 
di stingui sh between tiu·ee classes of particle ranges, which are important for the 
pu lmonary delivery: 1) the fine particles define the dose delivered to the deep lung, 
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the size ranges fTom O.Sfll1l to S,ll1l; 2) the coarse particles contribute mainly to 
oropharyngeal absorption, the size ranges from l OO,lm to 5flm ; 3) the extra fine 
particles are normall y exhaled and do not contribute to the delivered dose, the s ize 
range is smaller than O.5flm. 
Multi-colour measurements on the same sample of the cloud may show which co lour 
is scattered more than other co lours, and therefore, it might indicate the size range of 
particles in the cloud sanlple. Introducing a co lour paranleter and measlU"ing its 
temporal variation for the moving cloud might indicate, for example, the location of 
the fine particles in the cloud. It might be possible to remove, at least partl y, the 
ambiguity of the light obscurat ion, i.e. it may be possible to di stinguish between two 
situations, when the Sanle obscuration is caused by the smaller amount of the fine 
particles or by the larger amount of the coarse particles. 
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ApPENDIX 127 
Gelleral abbriviatiolls 
p-MDl pressurised metered dose 
inhaler 
OPI dry powder inhaler 
F flow rate 
t:J> pressure gradient 
R res istance to the flow 
LlIlIg Volllme Defillitiolls 
TV Tidal volume 
IRV Inspiratory reserve vo lume 
ERV Expi ratory reserve volume 
RV Residual volume 
FRC Functi onal res idual capacity 
Inspiratory capacity 
VC Vital capacity 
TLC Total lung capacity 
FEV 1 Forced expiratory volume 111 
one second 
III vitro assessmellt 
MMAO mass median aerodynamic 
diameter 
GSD geometric standard deviation 
FPO fine particle dose 
FPF fine particle fraction 
EO emitted dose 
MO metered dose 
VO vari dose system 
IlIertial impactioll systems 
T I twin stage impinger 
NGl next generation 
pharmaceutical impactor 
NOTATION AND GLOS ARY 
Particles 
d particle di ameter I l u l . 
aerodynam i cl geo met ricaJ 
r particle radius 
x dimensionless particle size 
parameter 
m refractive index for the particle 
material 
11, the number concentration for 
the i-type particles 
p material density of particles 
vP' vo lume ora single i-type 
particle 
Particle distriblltioll 
C, C •. , volume concentration 
/, fraction for the one type of 
particles in multi -species 
clouds 
mj 
N, 
mass of the one type of 
particles 
number of di fferent types of 
particl es 
N, Nez) particle number 
concentration 
the time coord i nate 
z, Zo spatial coordinate 
coordinate of the sensor 
Ii '" characteristic parameters of I' Y'I 
ApPENDIX 
Gaussian distribution for an 
individual type of particles 
cloud veloci ty 
128 
Model Notatioll 
a",b. Mie coefficients 
!fI", X", t;., Riccati-Bessel functions 
light wavelength 
L distance of the light 
propagation 
m2 refractive index for the 
medium 
n integer from I to infinity 
11, number for the Wiscombe 
cri terion 
Q,." ex tinction efficiency 
Cf, ex tinction efficiency for one 
type of particles 
y extinction coefficient 
I , I. radiation intensity 
T light tmnsmittance 
Obs light obscuration 
VariDose System 
d diameter of the collimated 
beam of light 
L diameter of the glass tube 
1 measurement period, detector's 
integration time 
Jf volume of tbe measurement 
.WnlIJif! 
sample 
Mathematical fitting procedure 
y = y, + Y2 fitting curve 
A,a,&,q,a, R,b fitting parameters 
NOTATION AND GLOS ARY 
Cloud characterisatiOIl 
H homogeneity 
A wal l residue 
FWI-IM fu ll width at the half 
maximum 
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